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  i 
Summary 
 
FAT10 (human leukocyte antigen F-associated transcript 10) is an 18kDA 
protein, which consists of 165 amino acid residues. It belongs to the ubiquitin-like 
modifier (UBL) family of proteins and encompasses two ubiquitin-like domains in 
tandem array. The sequence similarity between FAT10 and ubiquitin at its N- and 
C-terminal regions are 29% and 36%, respectively.  Since Ubiquitin is known to be 
involved in tumorigenesis, we hypothesized that FAT10 as an ubiquitin-like 
protein also played a role in tumorigenesis, since FAT10 has been reported to be 
overexpressed in several cancers, including colorectal cancer. Moreover, FAT10 
upregulation was previously associated with colorectal cancer progression. 
However, it remains unclear whether FAT10 plays a causal role in driving the 
malignancy of colorectal cancer, and if so, what the mechanisms involved were. 
Therefore, this study aimed to address the role of FAT10 in promoting the 
malignancy of colorectal cancer cells as well as to uncover the mechanism 
underlying FAT10’s role in driving tumorigenesis. In this thesis, we showed that 
FAT10 overexpression in a colorectal cancer cell line HCT116 facilitated cell 
proliferation compared to wild type- (WT) HCT116 as well as FAT10 stable 
knockdown- (FATi) HCT116 cells. Additionally, FAT10-overexpressing HCT116 
cells showed enhanced invasion in vitro as well as anchorage-independent growth 
in soft agar. Importantly, FAT10 overexpression in HCT116 promoted tumor 
growth in vivo based on xenograft mouse model. Having shown FAT10’s ability in 
supporting cell and tumor growth of colorectal cancer HCT116, we further 
investigated the role of FAT10 in non-tumorigenic cells. We have shown that not 
only was FAT10 overexpression able to enhance the malignant transformation of 
  ii 
cancer cells; it also conferred malignant transformation in the non-tumorigenic 
immortalized human neonatal hepatocytes (NeHepLxHT). Collectively, our results 
demonstrated the pro-malignancy functions of FAT10 in inducing cell 
proliferation, invasion and tumor growth in both colorectal cancer cells as well as 
non-tumorigenic immortalized hepatocytes. 
Previously, FAT10 was reported to interact with mitotic spindle checkpoint 
Mad2, which resulted in the reduction of Mad2 localization at the kinetochore 
during pro-metaphase and subsequent acceleration of mitosis duration, which led 
to aneuploidy. Aneuploidy, a hallmark of cancer cells, as well as aberrant functions 
of mitotic spindle checkpoint are both associated with tumorigenesis. In order to 
delineate the mechanism of FAT10 in tumorigenesis, we utilized nuclear magnetic 
resonance (NMR) technique to analyze the specific binding sites for Mad2 in 
FAT10 protein. Through NMR we found two FAT10-Mad2 interaction sites on 
FAT10 protein. Using fusion-PCR-mutagenesis method we mutated the specific 
amino acid residues in FAT10 protein obtained from the NMR protein-protein 
interaction study and we subsequently generated stable HCT116 cell lines 
overexpressing wild type FAT10 as well as FAT10 mutants with abolished Mad2-
binding function. Our findings confirmed that mutating both Mad2 binding sites on 
FAT10 abrogated FAT10 and MAD2 binding, based on co-immunoprecipitation 
and in situ proximity ligation assay (PLA), whereas mutation at either one of the 
Mad2-binding sites did not abolish the FAT10-Mad2 binding. Remarkably, this 
resulted in a decrease in the number of aneuploid cells and malignant cell 
behaviors in vitro, such as cell proliferation, survival, invasion and migration were 
observed. Importantly, the disruption of FAT10 and MAD2 interaction led to 
tumor regression in vivo. Thus far, we were able to confirm FAT10’s role in 
  iii 
aneuploidy and tumorigenesis. Our results suggest that Mad2-binding is an 
important mechanism by which FAT10 exerts its effect on cell malignancy. 
Therefore, based on our collective data, we have demonstrated that FAT10 exerts 
its pro-malignancy effects through disruption of mitotic spindle checkpoint via 
interaction with Mad2. 
In conclusion, we have, for the first time, demonstrated that FAT10 plays an 
important role in tumorigenesis and cell malignancy, consistent with the reports of 
FAT10 overexpression in human tumor samples. We have elucidated the specific 
Mad2 interaction sites on FAT10 protein and have also demonstrated that 
disruption of FAT10 and Mad2 binding significantly resulted in tumor regression 
in the in vivo xenograft model and reduced cell proliferation, migration, invasion 
and anchorage-independent growth in vitro. Our findings have unraveled FAT10 
as a crucial determinant of malignant cellular behaviors as well as its potential role 
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Chapter1 Introduction 
According to World Health Organization (WHO) cancer is the leading cause 
of death globally with an estimated 7.6 million deaths or around 13% of all deaths 
in 2008 (http://www.who.int/mediacentre/factsheets/fs297/en/). WHO has 
estimated that 84 million people will die in the next 10 years if no action is taken 
against cancer (http://whqlibdoc.who.int/publications/2007/9241547111_eng.pdf). 
However, the cure for cancer based on the current treatments available are still far 
from satisfactory (DeVita and Rosenberg 2012, Markowitz et al 2002). Therefore, 
more specific and targeted cancer research focused on understanding the 
mechanism of tumorigenesis, prevention, diagnosis and treatment need to be 
improved in order to tackle this serious disease. As third leading cancer related 
deaths (http://globocan.iarc.fr/factsheet.asp), discovering genes that contribute to 
the basic phenotypes of colorectal cancer (CRC) such as chromosomal instability, 
invasiveness and its metastatic spread has been carried out under intense research 
investigation (Hanahan and Weinberg 2011, Markowitz et al 2002, Markowitz and 
Bertagnolli 2009). Currently, surgery with resection of the affected segment is the 
most common treatment for colorectal cancer (Marin et al 2012) and clinical 
outcomes among the patients diagnosed at the same tumor stage are also variable 
(Galandiuk et al 1992). Hence, finding a new therapeutic target, which potentially 
causes the malignancy in colorectal cancer or biomarkers for diagnosis of CRC is 
needed. 
1.1 Colorectal cancer  
Worldwide, colorectal cancer is statistically reported to be the third leading 
cause of cancer-related deaths, with an annual occurrence of 1.2 million cases and 
mortality rate of more than 500,000 cases and its prevalence is constantly 
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increasing (http://globocan.iarc.fr/factsheet.asp) (Jemal et al 2010b). CRC is one of 
the most common cancers in the world, including Singapore (Figure 1.1). The 
mortality caused by CRC, much like any other solid tumors, is arise not from the 
primary tumor itself, but rather from its metastatic spread (Rajput et al 2008). 
Metastasis is a complex biological process, which involves multistep process such 
as changes in the extracellular matrix, which supports and increases cell invasion, 
motility, cellular extravasation, and also the ability of cells in initiating and 
maintaining growth at a distant site (Steeg 2003). Benign adenomatous polyp is the 
onset of this disease, which then develops into an advanced adenoma with high-
grade dysplasia and then finally progresses to an invasive cancer. Invasive cancers, 
which are contained within colon’s wall, are curable. However, those that are 
spread to regional lymph nodes or distant sites are more difficult to be cured and 
have a poor 5-year survival rate (Herszenyi and Tulassay 2010, Jemal et al 2010a, 
Jemal et al 2010b). Thus, understanding the molecular mechanism for CRC is 
needed to control this disease.  
CRC is developed over a multistep of colon neoplasia that extends over 
several years (Markowitz et al 2002) The risk factors of CRC include family or 
personal history of CRC or polyps, aging, inflammatory bowel disease, hereditary 
syndromes such as polyposis or nonpolyposis CRC, diabetes, smoking, and obesity 
(Amersi et al 2005, Knekt et al 1998, Markowitz et al 2002, Sandler 1996). Only 
about 20% of colorectal cancer has a familial basis (Rustgi 2007), some are 
associated with well-defined syndrome like hereditary non-polyposis colorectal 
cancer (HNPCC). Nevertheless, the biggest reason of colorectal cancer (CRC) has 
been linked to environmental causes, such as food-borne mutagens, specific 
Chapter 1 Introduction 
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intestinal pathogens, and chronic intestinal inflammation, which cause this disease 





Figure 1.1. New CRC reported cases in 2009 in representative countries 
worldwide. The graph presented above are based on 2009 WHO database of CRC 
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1.2 Hallmarks of cancers 
Genomic instability, which creates the genetic diversity, as well as 
inflammation, has long been proposed as the underlying cause of cancer 
development that leads to the several hallmarks of human cancers. These six well – 
known hallmarks or phenotypes of human tumors, which acquired during its 
multistep development, consist of sustaining proliferative signaling, evasion of 
growth suppressors, resisting cell death, enabling replicative immortality, 
induction of angiogenesis, and activation of invasion and metastasis (Figure 1.2) 
(Hanahan and Weinberg 2000, Hanahan and Weinberg 2011).  
In order to understand more about the biology of cancer, these six hallmarks 
of cancers play distinctive and complementary capabilities to prove the solid 
foundation of cancer development. 
 
Figure 1.2. The hallmarks of cancers. This figure depicts the six well-studied 
hallmarks of human cancers. Lots of research was done toward understanding the 
mechanism underpinnings of each hallmark. Adapted from Hanahan and 
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1.2.1 Aneuploidy and cancers 
An aberrant change in chromosome number or structure that is not exact 
multiple of haploid karyotype is known as aneuploidy and it is a type of 
chromosome abnormality. This condition is a common characteristic of solid 
tumor and it has long been proposed to contribute or even drive tumorigenesis 
(Kops et al 2005b, Torres et al 2008). In fact, approximately 90% of solid human 
tumors and about 75% of hematopoietic cancers were found to have aneuploidy 
(Weaver and Cleveland 2008). Errors in chromosome segregation or the 
occurrence of pre-mature anaphase during cell division are usually the reason of 
aneuploidy. The fact that it could promote aberrant mitotic division gives the 
evidence that it could also promote carcinogenesis, as aneuploidy is a characteristic 
of human cancers (Gordon et al 2012). 
Mitotic checkpoint or also known as spindle assembly checkpoint (SAC) 
play a major role in controlling the cell cycle process during mitosis. A tight 
control of cell cycle process by SAC acts as a prevention of chromosome 
misseggregation and its accompanying aneuploidy (Murray 2011, Weaver et al 
2008). Mitotic progressions from metaphase to anaphase and sister-chromatid 
segregation are controlled by anaphase promoting complex (APC/C), an E3 
ubiquitin ligase, its co-activator CDC20, as well as a group of spindle checkpoint 
proteins, which include Bub1, BubR1 (MAD3), Bub3, CENPE, MPS1, Mad1, 
Mad2, p31, ROD, Zwilch, and ZW10 (De Antoni et al 2005, Kops et al 2005b, 
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Protein Characteristics Binding partners Function in checkpoint  References 
BUB1 
122 kDa; serine/threonine 
kinase  BUB3 Inhibits CDC20 by phosphorylation (Tang et al 2004) 
BUBR1 
120 kDa; serine/threonine 
kinase CENPE, BUB3, CDC20 
Part of APC/C inhibitory complex. 





Sudakin et al 2001, 
Tang et al 2001)2 
BUB3  
37 kDa; structure determined: 
7-bladed propeller of WD40 
repeats BUB1, BUBR1 
Part of APC/C inhibitory complex. 
Localizes BUB1 and BUBR1 to 
kinetochores  
(Logarinho et al 
2008, Taylor et al 
1998)3 
MAD1  83 kDa; coiled coil  MAD2  
Directly recruits MAD2 to unattached 
kinetochore (Ryan et al 2012)3 





Part of APC/C inhibitory complex. 
Directly binds to CDC20 and inhibits 
APC/C activity 
(Fang et al 1998, 
Schuyler et al 2012, 
Yang et al 2008)3 
CMT2/p31
comet
  31 kDa; none identified MAD2  
Inhibits mitotic checkpoint signalling 
by antagonizing MAD2  
(Westhorpe et al 
2011, Yang et al 
2007)3 
MPS1 
97 kDa; dual-specificity 
kinase Unknown Unknown (Morin et al 2012)3 
CENPE 
312 kDa; plus-end directed 
microtubule motor BUBR1  
Activates BUBR1 at the unattached 
kinetochore 
(Yang et al 2010a, 
Yao et al 2000)3 
ZW10  89 kDa; none identified ROD, Zwilch  
Part of complex that recruits the 
MAD1–MAD2 heterodimer to 
unattached kinetochores (Kops et al 2005a)3 
ROD  251 kDa; none identified ZW10, Zwilch  
Part of complex that recruits the 
MAD1–MAD2 heterodimer to 
unattached kinetochores 
(Buffin et al 2005, 
Karess 2005)3 
Zwilch  67 kDa; none identified ROD, ZW10 
Part of complex that recruits the 
MAD1–MAD2 heterodimer to 
unattached kinetochores (Karess 2005)3 
 
Table 1.1 List of Mitotic checkpoint proteins. 
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As shown in Figure 1.3, in the process of mitosis in normal cells, SAC will 
bind to kinetochore (Musacchio and Salmon 2007), when spindle checkpoint 
detects errors in cell division, such as unattached kinethochore or lack of 
chromosome tension. It will give a “stop anaphase signal” to prevent the premature 
advance to anaphase, while it attempts to correct the mistakes (Khodjakov and 
Rieder 2009). The “stop signal” is consist of complexes of Bub3, BubR1, and 
Mad2 (Sullivan and Morgan 2007). These signals will then be transferred into the 
mitotic cytosol, where it will binds to APC/C co-activator CDC20 and inactivates 
the APC/C and CDC20 complex (APC/C –CDC20). Inactivation of APC/C-
CDC20 complex inhibits the binding to securin and cyclin B1, whereby it will 
prevents the advance to anaphase until the kinetochores are properly attached 
(Cleveland et al 2003, Peters 2002). As the chromosomes are correctly attached to 
microtubules, through their kinetochores and place under tension by spindle forces, 
Several SAC like MAD2, BubR1, BUB3, and MPS1 are rapidly released from the 
correctly attached kinetochore and the “stop anaphase signal” will be suspended 
and the inhibition of SAC to APC/C-CDC20 complex will also be acquitted 
(Howell et al 2004, Shah et al 2004). The activation of APC/C-CDC20 complex 
will then catalytically mediate the degradation of securin and cyclin B1, which 
leads to the activation of separase, which in mammalian cells its inhibition is 
associated with binding to securin and cyclinB1/Cdk1- mediated phosporylation. 
Further, separase cleaves the cohesin links that hold together the sister chromatid 
by cleavage of the chosein subunit Scc1 and initiates anaphase (Peters 2002, 
Taylor et al 2004, Weaver and Cleveland 2006). A tight control in metaphase to  
 
 






Figure 1.3. The mitotic checkpoint signaling in mammalian cells. A. During 
pro-metaphase, recruitment of MAD1, MAD2, MPS1, BUB1, BUB3, BUBR1, and 
CENPE to unattached kinetochore. This will inhibit APC/C-CDC20 to bind to 
Securin and prevent anaphase initiation. B). During anaphase, MAD2 is removed 
from kinetochore and active APC/C-CDC20 will bind to Securin and Separase will 
cleave Cohesins, which hold sister chromatid together and results in chromosome 
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anaphase progression ensures sister chromosomes to be evenly distributed and 
segregated into daughter cells (Kucej and Zou 2010, Pines 2006).  
Normal cells have an intact and robust mitotic checkpoint function, in which 
one or more unattached kinetochores are sufficient to inhibit all cellular APC/C 
activity and thereby block the premature anaphase (Rieder et al 1994). However, in 
the cancer cells the function of mitotic checkpoint might not be sufficient to 
control the mitotic progression. As a result if there are any chromosomes 
misalignment during metaphase, these cells are unable to generate sufficient 
inhibitory signal and resulted in premature progression into anaphase and 
chromosome misseggregation, which leads to aneuploidy (Kops et al 2005b). This 
malfunction in mitotic checkpoint proteins to give an efficient signal is one of the 
main factors that cause aneuploidy in cancer cells, and many studies have reported 
the lack or deficiency of these mitotic checkpoint proteins in human cancers 
(Hanks et al 2004, Rao et al 2005, Schuyler et al 2012, Schvartzman et al 2010). 
Mice that carried out a heterozygous deficient checkpoint such as Mad2 (Michel et 
al 2004, Michel et al 2001), BubR1(Baker et al 2012, Rao et al 2005), and Bub3 
(Baker et al 2006) have been reported to increase aneuploidy, which is one of the 
hallmarks of cancers.  
For nearly a century, genetic alterations such as insertion, mutations, and 
deletion of genomic DNA is always seen as the major cause of cancer (Hanahan 
and Weinberg 2011).  Rigorous efforts and studies have been done to prove on 
gene mutation hypothesis. However, so far, it is failed to identify the cancer-
specific mutation that could transform normal cells to become malignant cells, as 
well as to answer why that the occurrence of cancer only happens many months or 
even decades after mutation by carcinogens and why almost 90% of solid tumors 
Chapter 1 Introduction 
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are aneuploid (Weaver and Cleveland 2008), despite conventional mutation does 
not depend on karyotype alteration. In contrast, aneuploidy hypothesis seems to 
provide a better understanding and explanation about the cancer-specific 
phenotypes (Birchler and Veitia 2007, Duesberg and Rasnick 2000, Li et al 2000). 
Comparison with the conventional evolution of new species, aneuploidy can 
predict the long latent periods and the clonality based on these following two-stage 
mechanism: stage one, a carcinogen (or mutant gene) develops aneuploidy; stage 
two, aneuploidy destabilizes the karyotype and hence, initiates an autocatalytic 
karyotype evolution generating preneoplastic and eventually neoplastic karyotypes. 
Since the odds are very low that an abnormal karyotype will surpass the viability 
of a normal diploid cell, the evolution of a neoplastic cell species is slow and thus 
clonal. Moreover, aneuploidy based on the complexity of cancer-specific 
phenotypes, such as abnormal cellular and nuclear morphology, metabolism, 
growth, invasiveness, and metastasis, is more in accordance with the alterations of 
the dosage of thousands of regulation and structural genes than with gene 
mutations (Li et al 2000).  
 Strong evidences shows for high frequency of aneuploidy in cancer. 
Aneuploidy is claimed to be the second common form of genetic abnormality 
found in human cancers (Weaver and Cleveland 2006). Recently with the 
advancement in cytogenetic analysis, a comprehensive study from Beroukhim et al. 
is able to identify genomic regions that undergo frequent alterations in terms of 
somatic copy number alterations (SCNAs) in human cancers. He discovered that 
one quarter of a typical cancer cell’s genome is subjected to whole-arm SCNAs or 
whole-chromosome SCNAs of aneuploidy (Beroukhim et al 2010).  In addition, a 
strong evidence for preferential gain or loss in whole-chromosome SCNAs across 
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human cancer lineages was observed in their study, which shows that this is a 
selective process rather than random alterations. A reinforcement of the results 
from this study is further supported by the analyses of the Mitelman Database 
(http://cgap.nci.nih.gov/Chromosomes/Mitelman), which contains the largest 
repository of cytogenetic information on human cancer and the results of more 
than 60,000 cases (Ozery-Flato et al 2011). Concurrently, aneuploidy are also 
observed in several cancer types such as breast cancer (Li and Benezra 1996, Yoon 
et al 2002), colorectal cancer (Cahill et al 1998, Cardoso et al 2006), 
Hepatocellular carcinoma (Saeki et al 2002), lung cancer (Weitzel and Vandre 
2000), head and neck cancer (Ai et al 2001, Minhas et al 2003), and cervical 
cancer (Melsheimer et al 2004). In addition, in cases of acute myeloid leukemia 
(AML), 10-20% gain of chromosome number 8 is identified, as well as in some 
solid tumors like Ewing’s sarcoma and desmoids tumors (Hitzler and Zipursky 
2005, Maurici et al 1998, Qi et al 1996). All these data indicate the role as well as 
occurrences of aneuploidy at an early stage of tumorigenesis, which might support 
the preceding of cell transformation. 
Understanding about how aneuploidy contributes to the phenotypes of 
human cancer is still the focus in current research. One possibility is the ability of 
a population of cells reorganizes the whole chromosomes such as that it facilitates 
the loss of heterozygosity (LOH) of tumor-suppressor gene or gain of an oncogene 
by duplicating the chromosome that contains the mutated allele. One example that 
could explain this possibility is the high incidence of loss of chromosome 10 in 
gliobalstoma, which in turn resulting the inactivation of PTEN tumor-suppressor 
gene (Wang et al 1997). This study highlights that aneuploidy might contribute to 
tumor formation without the aid of additional mutations. The second possibility is 
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the defects or weakening of mitotic spindle checkpoint. In fact, loss in certain key 
mitotic checkpoint genes leads to aneuploidy and tumorigenesis in mice 
(Schvartzman et al 2010) as well as in human cancers (Schuyler et al 2012, 
Weaver and Cleveland 2006). Based on the current studies, it shows that mitotic-
spindle-checkpoint genes are often altered at the transcriptional level (Wang et al 
2002, Weaver and Cleveland 2006). Unravelling the mechanism behind this 
mitotic checkpoint and it defects could in the future provide a new prospect of 
treatment to target cancer. 
1.2.2 Mad2 
Mad2 (mitotic arrest deficient 2) is a 24-kilo Dalton (kDa) small protein 
without a discerning catalytic domain (Li et al 1997). It is an essential mitotic 
spindle checkpoint protein. The main role of Mad2 protein is to block the 
activation of separase and seperation of sister chromatids before the onset of 
anaphase until the chromosomes are properly aligned and attached at the 
kinetochores (Sotillo et al 2007). During checkpoint activation, Mad2 is activated 
with the help of Mad1. Physical interaction between Mad1 and Mad2 will function 
together in a hetero-tetrameric complex to initiate the “stop anaphase signal” 
(Chen et al 1999, Yang et al 2008). The Mad1-Mad2 complex will then bind at the 
unattached kinetochore, where Mad1 becomes hyper-phosphorylated and activated 
by the kinase monopolar spindle 1 (Mps1) (Hewitt et al 2010) (Figure1.3). Mad1-
Mad2 complex at the unattached kinetochore will catalytically form the Mad2-
CDC20 complex (Fava et al 2011). After being released from the kinetochore the 
Mad2-CDC20 heterodimer binds to other checkpoint proteins, which consist of the 
checkpoint protein Mad3 and Bub3. This Mad2-CDC20-Mad3-Bub3 complex is 
usually called the mitotic checkpoint complex (MCC). Finally, this MCC 
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inactivates the APC/C and leads to cell cycle arrest until all the chromosomes align 
correctly at the kinetochore. This mechanism will prevent the premature anaphase 
(Chao et al 2012, Musacchio and Salmon 2007). To dissolve MCC from the 
APC/C, Mad2 is bind to p31
comet
 also known as MAD2L1BP. The binding between 
Mad2 and p31comet will reactivate APC/C. The reactivation of APC/C will then 
activate separase and promote entry into anaphase (Varetti et al 2011, Westhorpe 
et al 2011). With this checkpoint process, MAD2 can help the premature intiation 
of anaphase until all chromosomes are properly attached and aligned along the 
kinetochore plate (Murray 2011). Either inactivation or hyperactivation of Mad2 
promotes tumorigenesis in mice (Chi et al 2009, Sotillo et al 2007). 
Mad2 is an essential gene not only in the tight regulation of cell division but 
it is also important during embryogenesis, because Mad2 null mice is 
embryonically lethal (Dobles et al 2000). Thus, complete inactivation of Mad2 has 
not been identified in human cancers (Michel et al 2004). However, in 
experimental mouse model, whereby one allele of Mad2 is deleted (Mad2+/-), 
shows higher cancer rates compared with its wild-type (WT) littermates. Mad2+/- 
mice developed an enhanced rate of lung adenocarcinoma after a long latency 
(Michel et al 2001). This suggesting that Mad2 haplo-insufficiency might 
contribute to aneuploidy and tumorigenesis.  
Mad2 dysregulation has long been implicated in various cancers. Attenuation 
of Mad2 expression associated with loss of mitotic checkpoint control and 
aneuploidy was observed in adult T-cell leukemia, breast cancer, ovarian cancer, 
and liver cancer (Weaver and Cleveland 2006). On the other hand, Mad2 
overexpression is seen in colorectal cancer (Li et al 2003) and gastric cancer 
(Wang et al 2009b). In addition, this abberant Mad2 overexpression was 
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demonstrated to be associated with inactivation of Rb or p53 tumor-suppressor 
gene, which resulting in mitotic alterations and aneuploidy (Schvartzman et al 
2011). Interestingly, only transient Mad2 overexpression can sufficiently promotes 
tumor formation, and knock down of Mad2 after tumor formation, did not result in 
shrinkage of existing tumor. This phenomenon shows that Mad2 is not required for 
tumor maintenance, unlike a classical oncogene. The lack of response of Mad2 
withdrawal after tumor formation reflects on the early induction of chromosome 
instability by Mad2, which would persist after Mad2 expression is normalized 
(Sotillo et al 2007). 
Deregulation of Mad2 function during mitosis might be also cause by the 
abberant interaction of Mad2 with the other proteins. As an example, 
overexpression of p31comet, a protein that inhibit mitotic checkpoint by 
antagonizing Mad2, induces premature degradation of securing and allows exit 
from mitosis without proper chromosome segregation (Habu et al 2002, Westhorpe 
et al 2011). 
In addition, microinjection of Mad2 antibody to the pro-metaphase of 
primary human keratinocytes induces premature anaphase, which leads to 
aneuploidy. However, although it is prematurely proceed to anaphase, the cells 
show a completed anaphase process including chromatid movement to the spindle 
pole as well as pole- pole separation post injection with Mad2 antibody. This 
shows how important Mad2 for the timing of anaphase onset in somatic cells 
during mitosis (Gorbsky et al 1998). Not only the expression level of Mad2 is 
important but also the localization of Mad2 in the cells undergoing mitosis is also 
essential for the exact anaphase entry. Higher eukaryotes change Mad2 localization 
in a cell cycle-dependent manner (Chen et al 1996). Despite its distribution 
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throughout the cell, Mad2 is preferentially found on the nuclear periphery (Kallio 
et al 1998). Fluorescence digital imaging reveals that at or near the onset of 
mitosis, Mad2 translocates into the nucleus. It localizes at the kinetochore from 
prophase to anaphase if the spindle attachment is incomplete or the chromosome is 
not properly aligned. Approximately 10 minutes after cells entered the anaphase, 
Mad2 fluorescence signal is no longer detectable on the kinetochores. 
Concomitantly, Mad2 can be found associated with unattached kinetochore after 
nocodazole treatment, a drug that interfere with microtubule polymerization 
(Howell et al 2000). Therefore, delocalization of Mad2 from the nucleus during 
mitosis could also lead to chromosomal instability or aneuploidy. 
1.3 Ubiquitin, ubiquitin-like proteins and cancer 
Since the discovery of ubiquitin pathway and functions in early 1980 
(Ciechanover 1994, Hershko and Ciechanover 1998), more and more intense 
research is focusing to dissect the regulation, mechanism and functions of 
Ubiquitin and Ubiquitin-like proteins. In fact, accumulation of evidence supports 
Ubiquitin and UBL to play a major role in wide variety of biological processes, 
such as DNA replication, DNA damage response, signal transduction, cell cycle 
control, embryogenesis, cell cycle progression, protein stability, apoptosis, 
transcriptional regulation, and many other functions (Mukhopadhyay and Riezman 
2007, Nakayama and Nakayama 2006, Tu et al 2012). Hence, aberrant or 
impairment function in the ubiquitin proteasome signaling is implicated in the 
etiology of many diseases, especially in tumorigenesis (Mani and Gelmann 2005). 
Moreover, ubiquitin-like proteins such as SUMO (Kim and Baek 2009), ISG15 
(Bektas et al 2008), and FAT10 (Lee et al 2003) have also been found to play a 
role in cancer development 
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1.3.1 Ubiquitin 
Ubiquitin is a small protein composed of 76 amino acids that is conserved 
across evolution from yeast to man and ubiquitously expressed in eukaryotes 
(Cook et al 1993, Yang et al 2010b). Cells are using ubiquitin as a covalent 
modifier of other proteins via an isopeptide bond between its C-terminal glycine 
and the -amino group of lysine in the substrate proteins both in order to activate 
their function as well as to target them for degradation via the 26s proteasome 
pathway (Hochstrasser 1996a, Hochstrasser 1996b). In a cascade of events that 
requires participation of three enzymes, ubiquitin is targeting its protein’s 
substrates for degradation. It is namely, the ubiquitin-activating enzyme (E1), the 
carrier protein (E2), and the ubiquitin ligase (E3) (Glickman and Ciechanover 
2002). The ubiquitin-activating enzyme (E1) initiates the ligation of ubiqutin by 
adenylation in an ATP-dependent manner, and then this ubiquitin molecule is 
transferred to the active site cysteine of ubiquitin-conjugating enzyme (E2) via 
trans-thioesterification reaction. In the final step, E2 works together with the 
ubiquitin ligase (E3) that is responsible for conferring substrate specificity. 
Ubiquitin is transferred to the internal lysine residue of the target protein and binds 
to its target via its C-terminal Glycine (Ciechanover and Iwai 2004). Emphasizing 
on the diversity of ubiquitin’s functions as a critical posttranslational modification, 
there are two different functional consequences to ubiquitin’s target proteins: 
monoubiquitination controls protein functions, ranging from membrane transport 
to transcriptional regulation(Di Fiore et al 2003), whereas ubiquitin chains that 
form through their lysine residue at position 48 (Lys48) are known to tag proteins 
for proteolytic degradation by the 26s proteasome (Hershko and Ciechanover 
1998). Conjugation of ubiquitin through other lysine residues (Lys6, Lys11, 
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Lys27, Lys 33, and Lys63) can form different lengths and shapes of ubiquitin 
chains. Thus, it shows that different ubiquitin chains’ conformation creates a range 
of molecular signal in the cell (Kim et al 2007).  
It is the fact that mutations and alterations in ubiquitination as well as 
deubiqutination process have been directly implicated in cancers (Ciechanover and 
Iwai 2004). For instance, the consequences of altered ubiquitination is stabilization 
of oncogene or destabilization of tumor suppressor gene products, which resulted 
from improper removal of oncoproteins that sometimes is part of the natural 
substrates of the ubiqutin system. Indeed, ubiquitin system target proteins that 
positively regulate cell proliferation, such as N-Myc, c-Myc, c-Fos, c-Jun, and Src-
like proteins as well as tumor suppressor proteins such as TP53, and p27 
(Confalonieri et al 2009, Sun 2006, Zhao et al 2008). Hence, ubiquitin machinery 
is recently under intense research in order to find a promising therapeutic target. 
As an example, a recently approved proteasome drug inhibitor called Velcade 
(Millenium Pharmaceuticals, Inc., Cambridge, MA, USA) has been used to treat 
multiple myeloma and mantle cell lymphoma (Orlowski and Kuhn 2008). 
However, this drug has only a limited function, because it targets only one 
functions of ubiquitin in protein degradation. Given a wide variety of functions in 
ubiquitin system, another aspect that needs to be considered are the undesired side 
effects from the drugs that targeting ubiquitin machinery.  
1.3.2 Ubiquitin –like modifiers (UBL) 
In addition to ubiquitin itself, many ubiquitin-like proteins have been identified. 
These ubiquitin-like proteins are related with ubiquitin either by its sequence or 
structure. Like ubiqitin, these proteins are engaged in vast array of vital cellular 
processes. Ubiquitin-like proteins are divided into 2 subgroups, ubiquitin-like 
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modifiers and ubiquitin domain proteins (UDP). Ubiquitin like modifiers (UBL) 
are proteins that contain ubiquitin-like structures (Jentsch and Pyrowolakis 2000). 
UBL has the same three-dimensional core structure as ubiquitin, where it adopts 
the conserved -grasp hold characteristic of ubiquitin (van der Veen and Ploegh 
2012). In addition, all UBL proteins comprised of a double glycine residue at its C-
terminal. This glycine residue is in charge of the covalent isopeptide binding with 
the lysine residue in its substrate proteins (Jentsch and Pyrowolakis 2000). First 
studies about UBL begun in the late 1980 by the discovery of an interferon-
stimulated gene product of 15kDA (ISG15). This protein has a sequence similarity 
with ubiquitin and also covalently modified other proteins (Haas et al 1987). 
Hitherto, there are 10 UBL proteins that are covalently linked to target proteins; 
these include NEDD8, FAT10, SUMO, ISG15, UBL5, Ufm1, Urm1, Atg8, Atg12, 
and FUB1 (Cajee et al 2012, Hochstrasser 2009) (Table1.2). Similar to ubiquitin, 
UBLs also uses a similar enzymatic cascade to target its substrate proteins (van der 
Veen and Ploegh 2012), with some exception that some UBL is capable to directly 
bind to its substrate without E3 (Hochstrasser 2009, Welchman et al 2005). So far, 
only SUMO2/3 and NEDD8 are known to participate in a chain formation like 
polyubiquitin chain (Matic et al 2008, Xirodimas et al 2008). UBLs is like 
ubiquitin, have a wide variety of cellular functions, such as activation of enzymes 
and transcriptional regulators, routing of proteins to their sub-cellular destination, 
mediating apoptosis as well as cell proliferation, and ultimately determination of 
the half-life of the target protein (Cajee et al 2012, Herrmann et al 2007). Apart 
from FAT10, none of the above-mentioned UBLs have ever been reported to be 
involved in proteasomal-protein degradation (Kerscher et al 2006, Welchman et al 
2005). 
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From all UBLs, SUMO is the most extensively studied (Herrmann et al 2007). 
It was first detected in mammals as a protein, which covalently bound to the 
GTPase activating protein RanGAP1 (Mahajan et al 1997). SUMO regulates 
various cellular biological processes, which encompass nuclear transport and 
organization, transcription, chromatin remodeling, DNA repair, cell cycle 
regulation and ribosomal biogenesis (Gareau and Lima 2010, Wilkinson and 
Henley 2010). Furthermore, substrate modification by sumoylation can affect 
protein-protein interactions, change protein intracellular localization, or even 
directly change the activities of the substrate proteins (Geiss-Friedlander and 
Melchior 2007). Several receptors and intracellular signaling proteins such as p53 
(Gostissa et al 1999), c-Jun (Muller et al 2000), and IB (Desterro et al 1998) have 
been demonstrated to be modified by SUMO and therefore contribute to 
tumorigenesis. Further, SUMO has also associated with several proteins that 
important in mitosis, these include condesin, Topoisomerase II (Top2), CENP-C/E, 
and surviving. Dysregulation of these proteins will then cause improper cell cycle 
process, which leads to aneuploidy and tumorigenesis (Dasso 2008). 
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 Table 1.2 List of ubiquitin-like modifiers and their function
Modifier Functions Acession Reference 
ISG15 
Function as an anti viral molecule, Modifying STAT1, 
SERPINA3G, JAK1, MAPK3/ERK1, PLCG1, 
EIF2AK2/PKR, MX1/MxA, and RIG-1.  
Interference with ubiquitin proteasome pathway. NP_005092 (van der Veen and Ploegh 2012, Zhao et al 2005) 
NEDD8 
Cell Cycle control and embryogenesis, Proteasomal 
degradation, 
Possible involvement in aggregosomes formation NP_006147  (Odagiri et al 2012, Rabut and Peter 2008) 
SUMO-1 
Nuclear transport, DNA replication and repair, mitosis, 
and signal transduction, cell cycle regulation NP_001005781  (Gareau and Lima 2010) 
SUMO-2 
Nuclear transport, DNA replication and repair, mitosis, 
and signal transduction, cell cycle regulation NP_001005849  (Gareau and Lima 2010) 
SUMO-3 
Nuclear transport, DNA replication and repair, mitosis, 
and signal transduction, cell cycle regulation NP_008867  (Gareau and Lima 2010) 
SUMO-4 
Negative regulator of NF-κB dependent transcription, 
Conjugation of stress defense proteins upon conjugation, 
modulation of protein subcellular localization  NP_001002255  (Bohren et al 2004, Wang et al 2009a) 
FAT10 
Protein degradation, mitotic non-disjunction and 
chromosome instability mediator, Regulation of TNF-
alpha induced chromosomal instability, Formation of 
aggresomes when proteasome is saturated or impaired. NP_006389 
 (Kalveram et al 2008, Rani et al 2012, Ren et al 2006, 
Ren et al 2011b) 
UBL5 p53 negative regulator NP_001041706  (Allende-Vega et al 2013) 
FUB1 
Regulation of apoptosis in human cells, LPS induced 
ERK-MAPK cascade NP_001988  (Nakamura and Yamaguchi 2006, Pickard et al 2011) 
Atg8 Mediates protein lipidation during autopagy  NP_009475  (Geng and Klionsky 2008) 
Atg12 
Mediator of mitochondrial apoptosis, Negative 
regulation of type I interferon production NP_004698  (Geng and Klionsky 2008, Rubinstein et al 2011) 
Ufm1 Prevention of ER stress induced apoptosis NP_057701  (Lemaire et al 2011) 
Urm1 Sulfur donor in biosynthesis pathway NP_001129419  (Van der Veen et al 2011) 
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Another class of ubiquitin-like molecule is called ubiquitin domain proteins 
(UDPs). UDPs have a higher primary amino acid sequence similarity compared to 
UBLs, but they are not conjugated to proteins (Herrmann et al 2007). Their cellular 
function is as an adaptor protein, whereby it binds non-covalently to ubiquitin or 
UBLs via its ubiquitin-associated domain (UBA). As an example of UDPs, Rpn10 
allows direct recognition of polyubiquitinated proteins by 26s proteasome 
(Elsasser et al 2002). The dysfunction of UDPs has been implicated to human 
diseases such as neurodegeneration and neoplasia (Madsen et al 2007).  
1.3.3 FAT10 
FAT10 (human leukocyte antigen F-associated transcript 10) is an 18kDA 
protein consists of 165 amino acid residues. FAT10 gene was first identified 
amongst genes in the HLA-F locus of major histocompatability complex (MHC)-
class I on chromosome 6, and found to be expressed in lymphoid cell lines. Thus, 
it was originally speculated to have a function in antigen processing and 
presentation (Bates et al 1997, Fan et al 1996). It belongs to the ubiquitin-like 
modifier (UBL) family of proteins and encompasses of two-ubiquitin like domains 
in tandem array (Jentsch and Pyrowolakis 2000). Thus, it is also known as 
diubiquitin or ubiqutin D (UBD) (Pelzer and Groettrup 2010). The sequence 
similarity between FAT10 and ubiquitin at its N- and C-terminal regions are 29% 
and 36%, respectively. Moreover, FAT10 at the C terminus region conserved the 
di-glycine residues from ubiquitin that are important for conjugating to its 
substrate protein. Lysine residue that may be capitalized as a potential site for 
polyubiquitination is also conserved in N-and C-terminal of FAT10 proteins (Liu 
et al 1999b). Four Lysine residues that correspond with polyubuquitin-chain 
formation, like Lys27, Lys33, Lys48, and Lys63, are conserved in both ubiquitin 
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like domains of FAT10 (Liu et al 1999b) (Figure 1.4). FAT10 is limited only to 
vertebrates and induced upon specific pro-inflammatory stimuli in specific tissue 
like spleen and thymus (Fan et al 1996, Gruen et al 1996, Liu et al 1999b). Highest 
basal expression of FAT10 was found in the cytoplasm of mature dendritic cells 
and B cells, which might show the involvement of FAT10 in immune response 
(Canaan et al 2006). The conjugation cascade of FAT10 has involved E1- 
activating enzyme UBA-6 (UBE1L2, E1-L2, OR MOP-4) (Chiu et al 2007, Pelzer 
and Groettrup 2010) and UBA-6 specific E2- conjugating enzyme, USE1 (Aichem 
et al 2010). So far, the specific E3 ligase of FAT10 has not been found. Covalent 
conjugation of FAT10 substrate proteins (FATylation) via its C-terminal glycine is 
hypothesized to target these proteins for proteosomal degradation (Hipp et al 2005, 
Raasi et al 2001). Unlike ubiquitin, FAT10 contains free di-glycine at its C-
terminus that does not require prior activation for the binding with its substrate 
proteins (Hipp et al 2005). Five substrates of FATylation have been found so far. 
These are its own E1-activating enzyme UBA6 (Chiu et al 2007), E2 conjugating 
enzyme USE1 (Aichem et al 2010), p53 (Li et al 2011, Zhang et al 2006), 
huntingtin (Nagashima et al 2011) and autophagic receptor p62 (Aichem et al 
2012a). However, FAT10 not only can bind covalently to the other proteins but it 
can also bind non-covalently with the other proteins. Several studies highlighted 
non-covalent interaction partners of FAT10 that leads to various cellular functions 
(Table 1.3). Interestingly, FAT10 can be significantly induced synergistically by 
pro-inflammatory cytokines such as tumor necrosis factor- (TNF-) and 
interferon (IFN) of almost all tissue origins (Lukasiak et al 2008b), this has 
further strengthened the possibility of FAT10’s roles in immune response and 
chronic inflammation. Further, elevated level of TNF is always detected in the 
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serum of HCC patients (Ataseven et al 2006) and colorectal cancer (CRC) 
(Szlosarek et al 2006). Concurrently, FAT10 overexpression was identified to 
associate with expression of TNF and IFN-dependent proteasome subunit 
LMP2; supporting that pro-inflammatory cytokines can induce both FAT10 and 
LMP2 (Lukasiak et al 2008b). Moreover, induction of FAT10 through TNF 
activates NF-B pathway and promotes chromosomal instability in colorectal 
cancer cells (Ren et al 2011b). Therefore, FAT10 is proposed to be the mediator in 
the development of chronic inflammation-associated tumorigenesis. 
Not only is FAT10 important in immune response, it also plays an important 
role in tumorigenesis. The important roles of FAT10 in cancer have been 
highlighted by several observations. Firstly, it is found to be overexpressed in 
various cancers, such as in 90% of Hepatocellular Carcinoma (HCC), and about 
85% of colorectal cancer (CRC) (Lee et al 2003). Secondly, FAT10 knockout mice 
exhibit spontaneous apoptotic death and are sensitive to endotoxin exposure of 
lymphocytes (Canaan et al 2006). Thirdly, FAT10 was identified as a potential 
marker for liver pre-neoplasia (Oliva et al 2008). Furthermore, FAT10 
overexpression in colon cancer and gastric cancer patients is reported to be 
associated with lymph node as well as distant metastasis, tumor staging, and 
invasiveness of these diseases. In gastric cancer, overexpression of FAT10 is 
associated with increased mutant p53 expression, which could further induce 
FAT10 expression and indirectly promote gastric cancer progression (Ji et al 2009, 
Yan et al 2010). Thus, in these studies, FAT10 protein and mRNA level is 
recognized as a prognostic marker for these diseases. Finally, FAT10 can also 
mediate pro-inflammatory cytokines TNF- in inducing chromosomal instability, 
which is one of the hallmarks of cancers (Ren et al 2011b). In accordance, FAT10 
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overexpression has also been reported to induce chromosomal instability (Ren et al 
2006). In summary, these observations support the notion that FAT10 plays an 
important role in tumorigenesis.  
Given the fundamental role of FAT10 in tumorigenesis and its pro-survival 
role, it is important for us to understand how cells can degrade FAT10, when it is 
no longer needed. Although it is still a debate, whether FAT10’s degradation is 
dependent or independent of ubiquitin, earlier study reported that FAT10-mediated 
degradation is independent of ubiqutination, as lysine-less FAT10 recedes. 
However, recent studies by Buchsbaum and Schimdtke et al. show that lysine-less 
FAT10 is degraded by the proteasome but it aggregates in an insoluble protein 
fraction (Buchsbaum et al 2012, Schmidtke et al 2006). In addition, as an 
alternative route for FAT10’s degradation, upon proteasomal inhibition, FAT10 
binds to histone deacetylase 6 (HDAC6) non-covalently and travels to aggresomes 
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Figure 1.4 Predicted 3D structure of FAT10 in comparison with Ubiquitin as 
well as its sequence comparison. A. Ribbon 3D structure of Ubiquitin and 
predicted 3D structure of FAT10 based on its sequence homology with ISG15 
(another di-ubiquitin like protein (http://www.uniprot.org/uniprot/P63072). B. 
FAT10 consists of two domains, where its sequence is in N-terminal (29%) and C-
terminal (36%) identical to ubiqutin. The double glycine motif is conserved in 
second domain of FAT10. Four Lysine residues (K27, 33, 48. 63), which play role 
in polyubiquitination chain formation, are also conserved in the two domains of 
FAT10. C. Sequence alignment of FAT10’s N- and C-terminal with Ubiquitin. 
(green: sequence is similar between FAT10’s N-terminal and ubiquitin, blue: 
sequence is similar between FAT10’s C-terminal and ubiquitin, red: sequence is 
similar in FAT10’s N-, C-terminal, and ubiquitin.
Ubiquitin 3D 
structure 
Predicted FAT10 3D 
structure 
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1.4 FAT10 and Mad2 
Using yeast-two-hybrid screening of human lymphocyte library, Mad2 is 
identified as a potential interaction partner of FAT10. Further validation using co-
immunoprecipitation reveals that FAT10 interacts with Mad2 non-covalently (Liu 
et al 1999b). Since Mad2 is a mitotic spindle checkpoint, which plays an important 
role for spindle assembly during anaphase, disruption of Mad2’s function during 
mitosis can result in chromosome missegregation, which leads to aneuploidy and 
tumorigenesis (Dobles et al 2000, Sotillo et al 2007). In support to these reports, 
our previous study demonstrates that FAT10 overexpression reduces Mad2’s 
localization to the kinetochore during pro-metaphase and abbreviates the mitotic 
duration, which then leads to aneuploidy (Ren et al 2006), one of the hallmarks of 
cancers (Weaver and Cleveland 2008). Furthermore, upon nocodazole arrest, cells 
overexpressing FAT10 are observed to escape mitotic arrest and become 
multinucleated in comparison with its parental cells, suggesting that FAT10 can 
help the cells escape from mitotic arrest, because its overexpression reduces Mad2 
localization at the unattached kinetochore during mitosis, which leads to 
uncontrolled cell cycle progression and aneuploidy (Ren et al 2006). Further study 
reveals similar results, when FAT10 is induced with TNF, such as delocalization 
of Mad2 from kinetochores, acceleration of mitosis duration, and the 
missegregation of chromosomes. Conversely, upon knockdown of FAT10 using 
FAT10siRNA, normal phenotype is restored (Ren et al 2011b). These evidences 
prove that FAT10 could possibly play a major role in driving tumorigenesis 
through its interaction with mitotic spindle checkpoint Mad2.  
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1.5 Objectives of this thesis 
In this thesis, I sought to accomplish three major objectives to elucidate the 
role of FAT10 in tumorigenesis that are further described below: 
1. To validate, whether FAT10 is a potential determinant of malignancy in 
colorectal cancer (CRC). To answer this question, in vitro study using cell 
proliferation-, apoptosis-, as well as invasion, and cell transformation assay 
were employed. In vivo, subcutaneous injection at the flanking region of 
nude mice of colorectal cancer cells overexpressing FAT10 is performed 
and compared with injection of parental cells. Indeed, in vitro and in vivo 
experiments shows that FAT10 overexpression could increase proliferation, 
protect these cells from apoptosis, encourage anchorage-independent 
growth, as well as increase its invasiveness. 
2. To find the specific site of FAT10 and Mad2 binding, which potentially 
could serve as a potential therapeutic target for cancer treatment. In 
collaboration with A/P Song Jianxing from Department of Biological 
Science, NUS, Nuclear Magnetic Resonance (NMR) was used to determine 
the three dimensional structure of FAT10 as crystal structure of FAT10 has 
yet to be elucidated. Chemical Shift perturbation mapping was used to 
determine the specific sites where Mad2 binds FAT10. Two-specific 
regions at domain one of FAT10 were found to be important for FAT10 
and Mad2 binding. 
3. To validate and characterize, whether the disruption of FAT10 binding to 
could reverse cell’s malignant behaviors, without disrupting FAT10’s 
physiological function. Using mutagenesis study complemented with 
various cell functional and transformation assays; we demonstrate the 
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significance of these specific regions of FAT10 and Mad2, which play in 
tumorigenesis. 
1.6 Significance of this thesis 
In this thesis, we present the first evidence the oncogenic property of FAT10, 
which could support the malignancy of colorectal cancer cells in vitro as well as in 
vivo. Previously, our lab has found that this malignant behavior was linked with 
FAT10 and Mad2 binding, which resulted in the Mad2 delocalization during 
metaphase, abbreviation of mitosis and leading to the dysfunction of Mad2 as 
mitotic spindle checkpoint during mitosis. 
I observed that FAT10 overexpression in vitro could induce cell proliferation 
and protect the cells from apoptosis in comparison with cells that did not 
overexpress FAT10. Additionally, FAT10 overexpression also enhanced the 
anchorage-independent growth of colorectal cancer cell on soft agar and increased 
its invasiveness, highlighting the important role of FAT10 as a potential 
determinant in colorectal cancer malignancy and its pro-survival roles. Finally, in 
vivo study using Xenograft mouse model also revealed that FAT10 could increase 
the tumor growth of these colorectal cancer cells, which has been injected 
subcutaneously into the dorsal flanking region of these mice. All these evidences 
mentioned above, emphasized the potential role of FAT10 as a potential drug 
target. However, targeting FAT10 as a whole protein could disrupt other important 
physiological functions of FAT10, since FAT10 is not only important in 
tumorigenesis, but it is also important in immune response and protein 
degradation. Therefore, delineating the regions within FAT10 that contributes to 
tumorigenesis is important.  
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Significantly, our findings further define the specific mechanism that can be 
exploited for colorectal cancer treatment. I have demonstrated that it is through 
targeting Mad2 specific regions within FAT10. Disruption of these specific sites 
inhibited the cell proliferation and tumor growth, as well decrease anchorage-
independent growth and invasiveness of these colorectal cancer cells. Not only 
could we see the reversed phenotypic effect through this disruption but we can also 
see that the cells were no longer aneuploid. Notably, I have also shown that 
disrupting these specific sites will not interrupt FAT10’s binding with the other 
proteins, especially those important proteins that involved for its proteasome 
degradation function, as FAT10 can still bind to its substrate proteins such as 
UBA6, and p62 via its C-terminal di-glycine residue, as well as its other non-
covalently reported interaction partners such as HDAC6, and NUB1L in these 
mutants. This work presents a significant improvement in our understanding on 
FAT10 as potential determinant in colorectal cancer cells malignancy as well as 
the specific mechanism that could be used as a potential drug target, which 
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Table 1.4 Overview of thesis 
Objective Findings Techniques 
To validate FAT10 as a 
potential determinant of 
malignancy in colorectal 
cancer CRC 
FAT10 increases cell 
proliferation 
WST-Assay and cell counting 
FAT10 protects cells from 
apoptosis  
Flow Cytometry with PE-AnnexinV Staining 
FAT10 increases the 
anchorage-independent growth 
of CRC cells  
Soft agar transformation assay 
FAT10 increases cell 
invasiveness 
Transwell-assay, F-Actin/Phalloidin Immunostaining and 
ELISA of Matrix metallopeptidase9 (MMP9) 
FAT10 increases cell adhesion 
and migration 
Adhesion assay with collagen coated plate and Wound healing 
assay 
FAT10 supports tumor growth Subcutaneous injection of CRC cells on the dorsal area of 
nude mice 
To find the specific site of 
FAT10 and MAD2 binding  
Mad2 binds to FAT10 at amino 
acid sequence number 11,13, 
73, 75, and 77 in domain 1. 
NMR study followed by chemical perturbation mapping in its 
HSQC spectrum to predict the specific site of Mad2 binding in 
FAT10 protein. (This work were performed by our collaborator 
A/P. Song Jianxing) 
To characterize and validate 
the specific site of FAT10 and 
MAD2 binding, which 
contributing in tumorigenesis 
FAT10 interacts with Mad2 co-Immunoprecipitation and Proximity Ligation Assay (PLA) 
Mutations of FAT10's amino 
sequence number 11, 13, 73, 
75, and 77 abolishes the 
binding between FAT10 and 
co-Immunoprecipitation and Proximity Ligation Assay (PLA) 
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Mad2 
Mutation of FAT10's binding 
site with Mad2 does not 
interfere with the other 
reported protein interaction 
partners of FAT10 
co-Immunoprecipitation and Proximity Ligation Assay (PLA) 
Mutation of FAT10 binding site 
with Mad2 inhibits cell 
proliferation 
WST-Assay 
Mutation of FAT10 and Mad2 
binding site prevents the cells 
from escaping the nocodazole 
arrest. 
Flow cytometry analysis with mitotic protein2 (MPM-2) 
staining 
Mutation of FAT10 and Mad2 
prevents the cells from 
aneuploidy 
Karyotyping of the chromosome number 
Mutation of FAT10 and Mad2 
binding site decreases the CRC 
cells invasiveness 
Transwell-assay, F-Actin/Phalloidin Immunostaining and 
ELISA of Matrix metallopeptidase9 (MMP9) 
Mutation of FAT10 and Mad2 
binding site decreases CRC 
cells adhesion and migration 
Adhesion assay with collagen coated plate and Wound healing 
assay 
Mutation of FAT10 and Mad2 
binding site inhibits tumor 
growth  
Subcutaneous injection of CRC cells on the dorsal area of 
nude mice 
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FAT10 In House 1:10000 rabbit polyclonal 
GAPDH (FL-
335) Santa Cruz sc-25778 1:20000 rabbit polyclonal 
HDAC-6 (D-11) Santa Cruz sc-28386 1:10000 mouse monoclonal  
MAD2 BD Biosciences 610679 1:10000 mouse monoclonal  
MTS-1 (X9-7) Santa Cruz sc-100784 1:5000 mouse monoclonal  
NUB1L (C-13) Santa Cruz sc-48059 1:5000 goat polyclonal  
p16 Santa Cruz sc-1661 1:10000 mouse monoclonal  
p62(Nucleoporin) Santa Cruz sc-48389 1:20000 mouse monoclonal  
PCNA (F-2) Santa Cruz sc-25280 1:20000 mouse monoclonal  
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Table 2.2 List of secondary antibodies used in thesis  
 
Secondary Antibody Company 
Working 
Dilution Source 
        
Goat anti-mouse IgG, HRP 
conjugated Pierce 1:80000 Goat polyclonal  
Goat anti-rabbit IgG, HRP 
conjugated Pierce 1:80000 Goat polyclonal  
Rabbit anti-goat IgG, HRP 
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2.1 Mammalian Cell Culture and Assays  
2.1.1 Mammalian Cell Culture  
All cell lines used in this thesis were purchased from American Type Culture 
Collection (ATCC, Rockville, MD, USA). Human colorectal cancer (CRC) lines 
HCT116 were cultured in McCoy’s 5A medium (Gibco/Invirogen, Carlsbad, CA, 
USA) supplemented with 10% FBS, while non-transformed immortalized human 
neonatal hepatocytes NeHepLxHT (ATCC CRL-4020) was cultured in Dulbecco`s 
Modified Eagle Medium/Nutrient F-12 Ham (Sigma, St Louis, MO, USA) 
supplemented with 0.2l/ml of Dexamethasone (Lonza/Clonetics, Allendale, NJ, 
USA), 0.25l/ml of Insulin (Lonza/Clonetics, Allendale, NJ, USA), 50g/ml of 
G418 (Promega, Madison, WI, USA) and 10% FBS. Flask and culture plates used 
for culturing of NeHepLxHT cells were coated with 0.03mg/ml rat-tail collagen-
type I (BD-Biosciences, Franklin Lakes, NJ, USA). The cell line was incubated at 
37C in a humidified atmosphere containing 5% CO2. 
2.1.2 Generation of stable HCT116 cell lines stably overexpressing WT-
FAT10 or mutant FAT10 
To engineer vectors expressing wild type (WT)-FAT10 or its mutants (FAT-
mL, FAT-mR, and FAT-mLR), Gateway Cloning Technology (Invitrogen, 
Carlsbad, CA, USA) was used to clone the FAT10 cDNA or mutant FAT10 cDNA   
downstream of the N-terminal of the CMV promoter of the destination vectors 
pcDNA3 (Invitrogen).  
To generate stable WT-FAT10 overexpressed cells and its mutants, 
colorectal cancer cell line (HCT116) was transfected with pcDNA3-FAT10, or 
pcDNA3-FATmL/mR/mLR using Lipofectamine2000 (Invitrogen) according to 
the manufacturer’s instruction. Cells were harvested 48 hr post transfection, and 
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then seeded onto a new 6-well plate with a 1:100 times dilution of cells containing 
McCoy’s5A medium (Sigma Aldrich, St.Louis, MO, USA) supplemented with 
10%FBS and 0.8mg/mL G418-sulfate (Promega, Madison, WI, USA). These cells 
were then incubated for 10 days at 37C in 5% CO2 humidified incubator. After 10 
days several colonies were selected and analyzed for its FAT10 expression by 
western blot using FAT10 rabbit polyclonal antibody (see Table2.1). Two stably 
FAT10 overexpressed or FAT10 mutant cells were selected for further functional 
analyses and studies.   
 
2.1.3 Recombinant adenovirus transduction of cells 
2.1.3.1 Generation of Recombinant FAT10 Adenoviruses 
An invaluable experimental tool used in this thesis is the control (Ad-Ctrl) 
and FAT10-expressing recombinant adenoviral (AdFAT10) system that facilitated 
efficient introduction of FAT10 protein into human neonatal hepatocytes 
NeHepLxHT cells. In this experiment, FAT10cDNA was initially subcloned into 
the shuttle vector pADTrack-CMV. The FAT10-containing pAdTrack-CMV-
FAT10 or control pAdTrack –CMV vectors was linearized using PmeI and 
subsequently co-transformed with enhance green fluorescence protein (EGFP) 
gene-containing pAdEasy-1 plasmid into BJ5183 E.Coli cells. Control and FAT10-
expressing recombinant adenoviral vectors were obtained by homologous 
recombination of the two vectors pAdEasy-1 and pAdTrack-CMV/p-AdTrack-
CMV-FAT10 respectively, and successful recombination events were screened 
using EcoRV and PmeI restriction endonuclease analyses. Subsequently, 
pAdControl and pAdFAT10 vectors were digested with PacI and transfected using 
Superfect Transfection Reagent (Qiagen, Hilden, Germany) into HEK293 cells 
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that constitutively express the adenoviral E1 gene product for packaging into 
control and FAT10-expressing recombinant adenovirus respectively. Finally, the 
titer of the viruses was determined by monitoring the number of green fluorescence 
cells after infection with serially diluted viral lysates and expressed as expression-
forming units/per ml.  
2.1.3.2 Infection of non-transformed immortalized human neonatal 
hepatocytes NeHepLxHT cells 
6x10
5
 NeHepLxHT cells were seeded at about 60% confluency in each well 
of 6-well plate and grown for 24 hours. AdControl or AdFAT10 adenoviruses were 
then introduced to the cells. Cells were transduced with a multiplicity of infection 
(MOI) of 20 for 24 hours. Fresh media was then added 24 hr post-transduction and 
cells were incubated for another 24hr before they were used for further analysis. 
Dark field and phase contrast images were taken 48 hr post transduction (Figure 

















                                         
Figure 2.1 Control and FAT10-overexpressing recombinant adenoviral 
system. A. Dark field and dark field overlay with bright field images of the cells 
infected with the indicated MOI. B. Western Blot of FAT10 and GAPDH loading 
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 HCT116 cells were seeded in each well of 6-well plate. 24 hour post 
seeding, 100M of short interfering RNA (siRNAs) or 4g of plasmid DNA were 
chemically introduced to the cells using siPORT Amine Transfection Reagent 
(Ambion, Austin, TX, USA) or Lipofectamine2000 (Invitrogen). These reagents 
were previously diluted in reduced serum media OPTI-MEM I (Invitrogen) in a 
10l: 250l ratio and incubated for 10 min at room temperature. Separately, 
siRNA or plasmid DNA was also diluted in 250l OPTI-MEM I. Subsequently, 
diluted siPORT Amine Transfection Reagent or Lipofectamine2000 were 
mixed with the diluted siRNA or plasmid DNA, and incubated for 25 min at room 
temperature. These transfection complexes were then added onto the adherent cells 
that were pre-washed with PBS and replaced with fresh culture media. Cells were 
then harvested 24 hr post-transfection for further analyses. SiRNAs specific for 
FAT10 (AM16708, Ambion), MAD2 (Hs-42213 and Hs-42214, Sigma) as well as 
scrambled siRNA (AM4611, Ambion)  were used as negative control in this study.  
2.1.5 Soft agar colony formation assay 
Anchorage independent growth using soft agar colony formation assay was 
performed in six well plates. First, 1.5 ml of 0.8% low-melting agarose solution 
(Invitrogen, Carlsbad, CA, USA) was added into each well and allowed to solidify. 
5000 cells then were mixed with 0.5 % low-melting agarose solution and added on 
top of the 0.8% solidified agarose gel. After the top layer has been solidified, 3ml 
of medium supplemented with FBS were given and the cells were cultured for 3 
weeks. The medium is continuously changed every 3-4 days during the 3 weeks 
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incubation. After 3 weeks colonies were stained with 0.01% methylene blue 
dissolved in 40 % methanol. 
 
2.1.6 Cell Growth Assay 
2.1.6.1 Cell Counting  
     The growth profile of HCT116/NeHepLxHT cells was determined by seeding 
these cells in 6-well culture plate. At various time points (0, 24, 48, 72, 96, 120 hr), 
cells were harvested, stained with trypan blue, and only viable cells were counted 
using hemocytometer.   
2.1.6.2 Cell proliferation assay 
     3 x 10
3
 cells were seeded in each well of 96-well culture plate (Corning Inc., 
New York, NY, USA) in 150 l of medium. After culturing cells at various time 
points (24, 48, 72, 96, 120 hr) the supernatant was removed and cell growth was 
determined using water soluble tetrazolium salt (WST-1) assay (Roche Applied 
Sciences, Penzberg, Germany) according to instructions given by the 
manufacturer. Absorbance was measured at 450nm using a microplate reader. All 
assays were carried out in triplicates.  
2.1.6.3 Determination of cell proliferation marker PCNA using FACS 
     For the analysis of PCNA expression, 1x10
6
 asynchronous cells were harvested 
and then fixed in 70% ethanol. Cell pellet was resuspended in Phosphate Buffer 
Saline (PBS) containing fluorescein isothiocyanate (FITC)-conjugated anti-PCNA 
or mouse IgG1 (BD Pharmingen) and incubated at room temperature in the dark 
for 30 min before staining with propidium iodide (PI; Sigma, St Louis, MO, USA). 
Stained cells were then analyzed using FACS Calibur instrument (Becton 
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Dickinson, San Jose, CA, USA). Dot plots were analyzed using WinMDi 2.9 
software. 
2.1.7 Invasion and cell migration assay  
The invasion assays were performed using Matrigel Invasion Chambers (BD 
Biosciences, CA, USA) and quantitated for the ability of the cells to invade across 
the coated membranes. Briefly, cells (5 × 10
4
/well) were suspended in McCoy’s 
medium supplemented with 0.1% bovine serum albumin and placed in the upper 
chamber of a 24-well Transwell apparatus containing Matrigel membranes. The 
lower chambers were filled with 750 µl of McCoy containing 10% FBS as the 
chemoattractant. After incubation for 36 hours at 37°C, medium was removed; 
cells were fixed with methanol and stained with Diff Quick (Siemens Healthcare 
Diagnostics, IL, USA). Cells on the upper surface of each membrane were 
removed with cotton swabs, whereas cells that had migrated to the bottom surface 
of the filters were counted using brightfield microscope. Total cell numbers were 
counted for each well. Each experiment was done with triplicate wells and 
repeated thrice. 
2.1.8 Cell adhesion assay 
Cell adhesion were performed in 6 well plate coated with collagen. Cells 
were then added to each well in triplicate and incubated for 30 min at 37C. Cells 
were washed 4 times with PBS and the remaining cells attached to the plates were 
observed under the microscope, harvested, and counted using a Beckman cell 
coulter counter (Beckman Coulter, IN, USA).  
2.1.9 Wound healing assay 
In brief, cells were plated on culture dishes to create a confluent monolayer. 
A wound was created by manually scraping the cell monolayer with a yellow tip 
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and the cells were washed and cultured with medium containing10% FBS. Cell 
images were then acquired at 0 and 24 hr after wound was created. 
2.1.10 Actin Cytoskeleton Immunostaining 
Cells were seeded on coverslips and incubated for 24 hr at 37C in a 
humidified atmosphere of 5% CO2. After 24 hr these coverslips with cells were 
then fixed with 4% paraformaldehyde in PBS for 15 min, washed with PBS, 
permeabilized in 1% TritonX-100 in PBS for 10 min, washed, and blocked with 
PBST with 1%BSA. To visualize the filamentous actin (F-Actin), the cells were 
stained with rhodamine-phalloidin (Invitrogen) for 30 min at 37C and washed 
with PBST. After final wash, coverslips were mounted on the slide glass using 
mounting medium (Sigma). The cells were then observed under a fluorescence 
microscope (Zeiss). 
2.1.11 Apoptosis Assay 
3x10
5
 stable overexpressing FAT10, FAT10 mutants, or wild-type HCT116 cells 
were seeded in 6-well plate. 24 hr after seeding, cells were subjected to 20M of 
Camptothecin (CPT) for 24 hours at 37C. The apoptosis profiles of the cells were 
analyzed by PE AnnexinV and 7AAD staining according to the manufacturer’s 
instructions (BD Biosciences Pharmingen, San Diego, CA, USA), followed by 
flow cytometry analysis using BD FACSCalibur (BD Biosciences). Subsequent 
analysis of the apoptotic profiles of the cells was analyzed using WinMDI2.9 
software (Joe Trotter, USA).   
2.1.12 Sample preparation for Karyotyping 
Cells were first synchronized for 17 hours in media containing 3 mM 
thymidine (Sigma). After 17 hr cells replace the old medium with a fresh medium 
without thymidine for 7 hr, then cells were treated with 0.1g/ml of colcemid 
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(Invitrogen) for 2 hours. Further, cells were harvested and rinsed with PBS, 
swelled in 0.06M of KCl solutions and fixed with methanol and glacial acetate 
acid in a 3 to 1 ratio. Fixed cells were dropped onto microscope slides, partially 
digested with trypsin, stained with Giemsa (Invitrogen). Chromosome number 
were counted using BandView software (Applied Spectral Imaging GmbH, 
Mannheim, Germany) under the phase contrast microscope (Zeiss).  
 
2.2 RNA/DNA methodology 
2.2.1 RNA isolation and reverse transcription polymerase chain reaction 
Total RNA was prepared from cells using Rneasy Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. Extracted RNA 
was then quantified using NanoDrop 1000 Spectrophotometer (Thermo 
Scientific, Waltham, MA, USA). For first strand cDNA synthesis, a 12l reaction 
volume consisting of 1g of RNA, 1 l of 50 M oligo dT primers, 1 l of 10 mM 
dNTP, RNase/nuclease free water and 1 l Superscript II Reverse Transcriptase  
(Invitrogen). Finally, this mixture was then incubated at 25C for 15 min followed 
by 42C for 1 hr and 70C for 15 min.  
2.2.2 Real-time polymerase chain reaction  
The abundance of transcription was determined by quantitative real-time 
PCR (qPCR) using ABI7500 Real Time PCR Detection System (Applied 
Biosystems, Life Technologies, Carlsbad, CA, USA). A 10 l reaction volume 
comprising of 5 l QuantiTect SYBR Green Master PCR mix (Qiagen), 0.25 
l each of forward and reverse primers (Table 2), and Rnase/nuclease free water 
was prepared. The following qPCR conditions were used: an initial denaturation 
step at 95C for 10 min, followed by 40 cycles of 95C for 30 sec, 58C for 30 sec 
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and 72C for 30 sec. All transcript abundance was normalized against a 
housekeeping gene -actin.  
2.2.3 Mini- and maxi-preparation of plasmid DNA  
QIAprep Miniprep Kit (Qiagen) was used for small scale DNA preparation, 
whereas NucleoBond Xtra Maxi EF kit (MACHEREY-NAGEL GmbH&Co., 
Dueren, Germany) was performed for large scale DNA preparation according to 
the manufacturer’s instructions.  
2.2.4 Agarose gel electrophoresis  
6x DNA loading dye was mixed with DNA and separated on a 1% agarose 
gel prepared by dissolving agarose in 1x TAE buffer (0.04M Tris-acetate, 0.001M 
EDTA) with addition of 0.5 g/ml ethidium bromide. The gel was run using 1 x 
TAE buffer, at 120 volts. DNA bands were visualized using UV trans-illuminator 
Gel Doc XR (Biorad, Hercules, CA, USA).  
2.2.5 DNA sequencing  
40 ng of plasmid DNA was utilized for ABI BigDye Terminator Cycle 
Sequencing (Applied Biosystem), with addition of the following reagents in a 10 
l reaction volume: 2.5 l BigDye Sequencing buffer, 0.5 l of 10 M primer, 0.5 
l BigDye Terminator v3.1 and deionized water. T3000 Thermocycler (Biometra 
GmbH, Goettingen, Germany) was used to perform the DNA sequencing with the 
following conditions: 25 cycles of 96C for 10 sec, 50C for 10 sec, 60C for 4 
min, then 4C on hold. These sequencing extension products were then purified 
using ethanol precipitation. Concisely to describe this step, 1 l of 250 mM EDTA, 
1 l 20 mg/ml glycogen and 50 l 100% ethanol was added into each tube.  Tubes 
were mixed well and centrifuged at 13,300 rpm for 30 min at 4C. The precipitated 
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DNA pellets were subsequently washed with 50 l of 70% ethanol, centrifuged at 
13,300 rpm for 15 min at 4C and air-dried for 15 min at room temperature. 
Finally, DNA pellets were resuspended in 10 l highly deionized (Hi-Di) 
formamide (Applied Biosystem) and sequenced using ABI 3100 Genetic Analyzer 
(Applied Biosystems).  
2.2.6 Generation of FAT10 and mutant-FAT10 constructs   
To experimentally validate the specific binding sites between FAT10 and 
MAD2 that has been predicted via nuclear magnetic resonance (NMR) study by 
our collaborator A/P Song Jianxing, WT-FAT10 and FAT10 mutant constructs 
(FAT-mL, FATmR, FATmLR) were generated. First, a 1006 bp FAT10 fragment 
was PCR amplified from genomic DNA of non-tumorous human liver tissue using 
Expand High Fidelity PCR System (Roche Applied Sciences, Penzberg, Germany) 
and primers 5`-GAGAGGATCCATGGCTCCAATGCTTCCTG-3`(forward) and 
5`-TATAGCGGCCGCCCCTCCAATACAATAAGATGC-3` (reverse) in a total 
volume of 20l. The conditions for PCR used are as follows: initial denaturation at 
95C for 2 min, 10 cycles of 95C for 15 sec, 55C for 30 sec, and 68C for 4 min, 
followed by another 10 cycles of 95C for 30 sec, 55C for 30 sec, and 68C for 4 
min with 5 sec cycle elongation of each successive cycle, and a final elongation at 
72C for 7 min. This amplified FAT10 fragment was then gel-purified and cloned 
behind the CMV promoter into the BamHI/NotI in pCDNA3 plasmid (Invitrogen). 
The plasmid construct also contained ampicillin for plasmid amplification in 
E.Coli as well as Neomycin for stable cells selection. The following mutant 
FAT10 constructs were generated: a) mutant FAT10 at regions I (FAT-mL), b) 
mutant FAT10 at regions II (FAT-mR) c) double FAT10 mutant containing 
mutations at both regions (FAT-mLR) d) mutant FAT10 at its C-terminal double 
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glycine residue (FAT-Gly) from Glycine to Alanine e) mutant FAT10 at its all 
lysine residue in both domains (FAT-Lys) from Lysine to Arginine. The mutant 
FAT10-constructs (FAT-mL, FAT-mR, and FAT-mLR) were generated by fusion 
PCR using primers consisting the desired mutations (Figure 2.2). We would like to 
apologize that the exact sequence of the Mad2 interaction regions in FAT10 cannot 
be revealed in this thesis as we are only in the process of getting it patented.  
 The fusion PCR conditions are as follows: an initial denaturation at 95C for 
15 min, followed by 20 cycles of 95C for 30 sec, 50C for 30 sec, and 72C for 3 
min. The amplified fragments was gel-purified and similarly cloned into the 
pcDNA3 plasmid downstream of the CMV promoter. Sequencing of all the 
constructs to verify the DNA sequence’s integrity was performed. This will allow 
us only to choose construct with only the desired mutations.  
Figure 2.2 
          
Figure 2.2 Pictorial diagrams for generation of FAT10 mutant-contructs. 
Introduction of mutations in Mad2 interaction regions within FAT10 via fusion-
mutagenesis PCR method. The arrows shows the primers used to clone the FAT10 
mutant-constructs (FAT-mL, FAT-mR and FAT-mLR).  
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2.3 Protein Methodology  
2.3.1 Isolation and quantification of proteins from cells 
Cells were harvested and pellet down from the cell culture flasks/plates. Cell 
pellets were then lysed with 100 l of RIPA buffer (50 mM Tris HCl pH 8, 150 
mM NaCl, 1% NP-40, 0.5.5 sodium Deoxycholate, 0.1% SDS) and incubated on 
ice for 30 min. Cells were sonicated using Bioruptor (Diagenode Denville, NJ, 
USA) for 10 min at high setting with 30 sec ‘on’ followed by 30 sec ‘off’. Cell 
debris was removed by centrifugation at 13,300rpm for 2 min at 4C and cell 
lysates were transferred to new tubes. Protein concentrations were determined 
using Bradford protein assay reagent (Bio-Rad) according to the manufacturer’s 
instructions.  
2.3.2 Western Blotting 
6 x SDS-loading dye was mixed with 60 g of protein sample. The mixture 
was boiled for 10 min and subjected to gel electrophoresis on a 13% SDS poly-
acrylamide gel. The separated proteins were transferred to a polyvinylidene 
fluoride membrane (Bio-Rad), blots were blocked for 1 hr using Amersham ECL 
membrane blocking agent (GE Healthcare Biosciences, Uppsala, Sweden). The 
appropriate primary antibodies (Table 2.1) were then added to the blot and 
incubated for 1 hr. After primary antibody incubation, blots were washed with 
PBST (1 x PBS + 1% Tween-20) for 15 min and then incubated for 45 min with 
the appropriate horseradish peroxidase-conjugated secondary antibodies (Table 
2.2). Following the secondary antibodies incubation and washing steps, protein 
signals were detected using Amersham ECL Western Blotting Detection 
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Reagents (GE Healthcare). Finally, the membrane was exposed on a Koadak 
BioMax MR film (Kodak Inc., Rochester, NY, USA).  
2.3.3 Immunoprecipitation  
Cells were transfected with Lipofectamine2000 (Invitrogen) as a control or 
Lipofectamine2000 carrying FAT10 gene. After 24 hr, cells were harvested and 
lysed using RIPA buffer. Cell debris was removed using centrifugation at 
13,300rpm and the protein concentration of the protein lysate was measured and 
adjusted to 3 mg/ml. Immunoprecipitation was performed using the protein G-
immunoprecipitation kit (Roche Applied Science, IN, USA) on 600 g of the 
protein lysate with 2 μg of either of the following antibodies: p16 antibody (Santa 
Cruz Biotechnology, Santa Cruz, CA, USA), which served as a nonspecific rabbit 
IgG control; mouse monoclonal MAD2 antibody (BD Biosciences, Franklin Lakes, 
NJ, USA); mouse monoclonal UBA6 antibody (Sigma), mouse monoclonal 
HDAC6 (Santa Cruz); NUB1L goat polyclonal antibody (Santa Cruz) and rabbit 
FAT10 antibodies generated by our laboratory. The immunoprecipitated proteins 
were then subjected to gel electrophoresis in 13% SDS poly-acrylamide gel, and 
western blot analyses was performed as described previously using FAT10, 
MAD2, UBA6, NUB1L or HDAC6 antibodies. 
2.3.4 In-situ Proximity Ligation Assay (PLA) 
Cells were seeded on an 8-chamber slide (Thermo Scientific, Waltham, MA, 
USA). PLA (Duolink in situ PLA™; Olink Bioscience, Uppsala, Sweden) was 
carried out to detect the protein-protein interaction between FAT10, MAD2, and 
the other reported interaction partner of FAT10. Rabbit FAT10 antibody generated 
by our lab (dilution: 1:300) was incubated together with following antibodies: 
mouse MAD2 antibody (BD) or mouse UBA6 antibody (Sigma), or mouse 
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HDAC6 antibody (Santa Cruz), or mouse NUB1 antibody (Santa Cruz), or mouse 
p16 antibody (negative control) with a dilution of 1:100 was used. The cells were 
incubated overnight at 4C with the two antibodies pair mentioned above. To 
visualize the bound antibody pairs, the Duolink Detection Kit HRP/NovaRED with 
PLA plus and minus probes for mouse and rabbit (Olink Bioscience) was used, 
according to the manufacturer’s description. After washing, specimens were 
mounted with the Duolink DAPI Mounting Medium (Olink Bioscience). The PLA 
signals were then observed under the fluorescence microscope (Zeiss) with 200x 
magnification. (Figure 2.2)  
 
2.4 Statistical analysis of experimental data 
Data presented in this study were obtained from at least three independent 
experiments, unless otherwise stated. Data were presented as mean values of 
experimental triplicates  standard error (SE). Data comparing differences between 
two groups were statistically analyzed using two-sided unpaired Student’s t-test. 



















Figure 2.3 Schematic presentation of in situ proximity ligation assay (PLA). A. 
Dual binding by a pair of proximity probes that consist of antibodies with attached 
DNA strands to a target protein complex that interact with each other. B. The 
probes that come in proximity because of the specific protein-protein interaction 
will serve as the hybridization of circularization of oligonucleotides, which are 
then joined enzymatically by ligation into a circular DNA molecule. C. The 
circular DNA will then be amplified by rolling circle amplification (RCA) primed 
by one of the proximity probes. This will create a concatemeric RCA product that 
remains covalently attached to the proximity probe. Fluorophore-labeled detection 
primers are then hybridized to the repeated sequence of the rolling circle products, 
and these will creates a bright signal that could be visualized under the 
fluorescence microscope.  
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Chapter 3 Results 
 
3.1 FAT10 enhances cell proliferation of HCT116 colorectal cancer cells 
Previous findings in our lab revealed that FAT10 is overexpressed in 
gastrointestinal cancer and colon cancer and also its ability to induce chromosomal 
instability (Lee et al 2003, Ren et al 2006). We used wild-type (WT) colorectal 
cancer HCT116 cell lines, wild type FAT10 stably overexpressing cells (FAT10), 
and transient knockdown of FAT10 overexpressing stable cells using 
FAT10siRNA (FATi) to study the malignant transformative potential of FAT10 
especially in enhancing cell proliferation, as it is well-known that sustaining cell 
proliferation is one of the hallmarks of cancers.  
In order to answer this question, I generated two stable cell lines, namely two 
stable cell lines overexpressing wild type FAT10 (FAT-A & FAT-B). As shown in 
Figure 3.1.A by Western blot as well as real-time PCR, the basal level of FAT10 is 
undetectable in wild type HCT116 cells and very low in FATi cells, in comparison 
with FAT10-overexpressing cells, which showed high expression level of FAT10.  
Cells expressing high levels of FAT10 showed significant enhancement in cell 
proliferation in vitro, as determined by the trypan-blue exclusion cell counting 
method for a period of 3 days or WST- calorimetric assay over a period of 5 days 
(Figure 3.1B upper panel). The cell doubling time of FAT10 overexpressing cells 
were also higher in comparison with the WT cells (Figure 3.1 B bottom panel). 
Cell proliferation rate of FATi cells was similar to wild-type HCT116 cells (WT) 
but significantly reduced after FAT10 expression was knocked down in FAT10 
overexpressing stable cells (Figure 3.1.B upper panel). These results implicate 
FAT10’s role in modulating cell proliferation. 








Figure 3.1 FAT10 enhances cell proliferation. A. Expression level of FAT10 by 
Western blot (left panel) and real-time PCR (right panel) in wild type (WT) 
HCT116, FAT10 stably overexpressing HCT116 (FAT-A, FAT-B) cells, and 
transient FAT10-knocked-down cells (FATi). B. Cell proliferation profile from 
WT HCT116 and the stably transfected cell lines, determined by trypan blue 
exclusion cell counting method (top left panel) or by WST-cell proliferation assay 
(top right panel). Cell doubling time is calculated as d = log2/k where k is the 
growth constant determined by the slope of the linearly regressed line. FAT10-
overexpressing cells have significantly shorter cell doubling time compared to WT 
or FATi (bottom panel). Data is expressed as mean+s.e. of at least three replicates. 
*denotes statistical significance at p-value<0.05 compared with WT, **denotes 
statistical significance at p-value<0.01 compared with WT. 
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3.2 FAT10 upregulates cell proliferation marker Proliferating Cell Nuclear 
Antigen (PCNA) 
Complementary to the proliferation assay described in Figure-3.1, bivariate-
flow-cytometric analysis was used, to assess cells expression of proliferation 
marker, Proliferation Cell Nuclear Antigen (PCNA), which is expressed in the 
proliferating cells, and propidium iodide (PI) staining for the cell cycle phase. 
Through flow cytometry analysis using WinMdi2.9 software (Purdue University, 
USA), we observed that FAT10 overexpressing cells (FAT-A and FAT-B) 
expressed at least 1.5 times more PCNA positive cells in comparison with WT 
HCT116 cells (Figure 3.2 A). Western blot analysis to check the protein level of 
PCNA, as well as real- time PCR to analyze the transcript level of PCNA also 
showed the upregulation of PCNA expression in FAT10 overexpressing cells. In 
combination with our data from trypan blue cell counting method and WST-assay, 
these data together again further strengthened our hypothesis that FAT10 can 
significantly increase the cell proliferation of HCT116 colorectal cells.  
3.3 FAT10 encourages anchorage-independent growth of HCT166 cells. 
Since FAT10 enhance cell proliferative properties of the cells, I further 
investigated its impact on supporting anchorage-independent growth. Soft agar 
transformation assay was used to demonstrate the ability of FAT10 in encouraging 
the cells to form colonies. The ability of cells to form colonies in anchorage-
independent condition is one of the hallmarks of transformed malignant cells. As 
shown in Figure 3.3, FAT10 significantly increased the colony formation of 
HCT116. In contrast to WT cells, which in average formed around 5216.7 
colonies of cells in soft agar, FAT10-overexpresing cells have the ability to form a  
 








Figure 3.2 FAT10 increases the level of cell proliferation marker PCNA. A. 
Comparison of PCNA positive cells using Flow-Cytometry analysis (FACS) of 
WT, FAT-A, FAT-B, and FAT-C cells. Prior of the FACS analysis, these cells 
were stained with PCNA-FITC reagent. The histogram at the upper left represents 
the comparison of the PCNA-positive cells analyzed using Win.Mdi2.9 software. 
The graph at the bottom left showed the percentage of PCNA-positive cells based 
on the FACS analysis. Data is expressed as mean+standard error with at least three 
replicates (*p<0.05). B. FAT10 expression level validated by real-time-PCR 
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higher colonies number (273 + 63.2 cells in FAT-A, 258 + 43.5 cells in FAT10-B) 
(Figure 3.3). However, knockdown of FAT10 using siRNA attenuated the ability 
of FAT10 stable overexpressing cells to form colonies. An average of 63 + 8.9 
colonies of FATi cells comparable with WT cells were observed in soft agar. 
FAT10 increased the formation of colonies in soft agar by at least 4 fold compared 
to WT and FATi cells, which have a low expression of FAT10. This has further 
strengthened our notion that FAT10 is a potential determinant that can drive the 
malignant transformation of cancer cells.  
 
3.4 FAT10 promotes cellular transformation of non-tumorigenic NeHepLxHT 
cells 
Not only can FAT10 support anchorage-independent growth of HCT116 cells, but 
it is also able to drive the transformation of non-tumorigenic human neo-natal 
hepatocytes (NeHepLxHT). Recombinant FAT10 adenovirus were generated and 
NeHepLxHT cells were infected with the adenovirus-carrying vector control 
(AdCtrl) or adenovirus overexpressing FAT10 (AdFAT10) under the optimal MOI 
as shown in Figure 2.1. Only NeHepLxHT cells infected with AdFAT10 were able 
to form colonies in soft agar (Figure 3.4). An average of  14.5 1.66 colonies 
were observed in NeHepLxHT cells overexpressing FAT10, while no colonies 
were observed in wild type NeHepLxHT cells and NeHepLxHT cells infected with 
adenovirus vector control (AdCtrl). The ability of FAT10 infected NeHepLxHT 
cells to survive under anchorage-independent conditions is one of the evidence that 
FAT10 can promote the transformation of “normal” cells to become malignant 
cells. 
 





Figure 3.3 FAT10 supports anchorage-independent growth. Anchorange-
independent growth and colony formation were assessed by growing WT and the 
stable cell lines in soft agar as described in Material and Methods. 5000 cells were 
seeded into each well. Cells were grown for 3 weeks at 37C in 5% humidified 
CO2 incubator. After 3 weeks soft agar were stained and colony number was 
quantified. The HCT116 colonies were photographed at 20x magnification (bottom 
panel). A significant result of FAT10-overexpressing cells exhibit the ability to 
survive and growth under anchorage-independent condition compared to WT and 
FATi cells. Data is expressed as mean+standard error with at least three replicates. 


















Figure 3.4 FAT10 promotes cellular transformation of non-tumorigenic 
hepatocytes (NeHepLxHT). As shown in the pictures above only NeHepLxHT 
cells infected with AdFAT10 are able to form colonies (red arrows indicates the 
formation of colonies). In average approximately 14.5 1.66 colonies were formed 
(lower panel). Cells were incubated for 4 weeks at 37C, pictures were taken under 
microscope with 20x magnification and colonies were then quantified. Results 
were taken from 3 biological repeats. ** denotes p-value < 0.01. 100.000 cells 
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3.5 FAT10 protects cells from cytotoxic induced cell death 
One of the other hallmarks of cancer is the ability of cells to resist cell death. 
To demonstrate the ability of FAT10 in protecting the cells from apoptosis, WT 
HCT116 cells as well as FAT10 and FATi cells were treated with Camptothecin. 
Camptothecin is a cytotoxic agent that inhibits DNA replication. Cells were treated 
with 20 M of Camptothecin for 24 hr. Cells were then harvested and stained with 
PE-Annexin V followed by flow cytometry analysis. Morphologic features, 
including the loss of plasma membrane attachment and asymmetry, were used to 
characterize apoptotic process. In apoptotic cells, the membrane phospholipid 
phosphatidylserine (PS) is translocated from the inner to the outer site of plasma 
membrane, therefore exposing its PS to the external cellular environment. Annexin 
V has a high affinity for PS and binds to cells with exposed PS. Thus, Annexin V-
positive cells indicate that the cells are undergoing apoptosis.  
PE-Annexin V staining showed that FAT10-overexpression in HCT116 cells 
conferred protective effect against camptothecin-induced cell death, where the 
population of apoptotic cells in FAT10 overexpressing cells is approximately 
around 7.55 + 0.6% for FAT-A and 5.59 + 0.8% for FAT-B versus 20.46 + 1.2% 
for WT. Similar rate in apoptotic cells population was observed in FATi cells 
(21.61 + 0.4%) compared to WT, when FAT10 expression was inhibited (Figure 
3.5A, B). Similarly, using trypan blue cell counting method, where dead cells that 
were stained with trypan blue dye were counted using haemocytometer (Figure 
3.5C). Similar results were observed with PE Annexin V staining, whereby FAT10 
protected the cells from cytotoxic induced cell death. These observations indicate 
that FAT10 overexpression not only enhances cell proliferation but it could also 
facilitate cells resistance against cell death. 




Figure 3.5 FAT10 protects cells from cytotoxic induced cell death. Cells were 
treated with cytotoxic agent 20M Camptothecin for 24 hr A. Shown are staining 
profiles of a representative set of experiments. The apoptotic cells are depicted in 
the upper left quadrant (Annexin V positive, 7-AAD negative). B. Apoptosis 
profiles of WT, FAT10 overexpressing, and FATi HCT116 cells determined using 
PE-Annexin V and 7-AAD staining, followed by flow cytometry detection and 
analysis. Shown are the percentages of apoptotic cells distribution described in B 
from 3 independent biological repeats. C. Shown are the percentages of dead cells 
(trypan blue positive cells) from 3 independent experiments in WT, FAT10 
overexpressing, and FATi HCT116 cells. Error bars shows SE (Standard error) 
from 3 different experiments. ** denotes p-value < 0.01. 
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3.6 FAT10 increases HCT116 cells invasiveness 
Beside increasing cell proliferation, malignant transformation of cells, and 
resistance of cell death, the ability of FAT10 to affect cells malignancy, such as the 
gain of invasive capabilities was also observed. The role of FAT10 in enhancing 
the invasiveness of HCT116 cells was examined using plates carrying Transwell 
inserts, which comprised cell permeable membrane. In order to mimic the presence 
of tumor cells microenvironment in vivo, Transwell inserts were coated with 
matrigel. This matrigel will serve as an extracellular matrix, which are normally 
presents in tumor cells microenvironment and are degraded during invasion 
process by the tumor cells. By seeding the cells on top of the insert, which has 
been coated with collagen, plus an additional chemo-attractant (FBS) at the bottom 
of the inserts, the invasive features of the cells can be determined by staining and 
counting those cells that have transversed the cell permeable membrane towards 
the higher concentration of chemo attractant. This assay revealed that FAT10 
overexpression significantly augmented the pro-invasive function of FAT10 across 
the collagen-coated wells by at least 5 fold in comparison with WT HCT116 cells 
that have a low level of FAT10. (Figure 3.6A). 
The dynamic of actin-cytoskeletal remodelling and the formation of protrusive 
structures in FAT10 overexpressing- and WT HCT116 cells, which are required 
during the invasion process, were also examined. Rhodamine-phalloidin staining 
was used to examine the actin cytoskeleton.  Phalloidin is one of a group of toxins 
from death cap (Amanita phalloides) and binds specifically to F-actin. As shown in 
Figure 3.6B, immunofluorescence revealed that FAT10 overexpressing cells 
displayed more intense F-actin staining than WT cells. Further, FAT10  
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overexpressing cells also exhibited prominent lamellopodia-migratory structures, 
which are observed in Figure 3.6B as broad extension from plasma membrane. 
Taken together, all these data show the role of FAT10 in driving the invasiveness 
of tumor cells during tumorigenesis. 
3.7 FAT10 promotes cell migration and adhesion 
Other important attributes of malignant cells are its ability to migrate as well 
as to adhere to extracellular matrix. Therefore, using scratch-wound healing assay, 
we examined the ability of FAT10 overexpressing cells and WT cells to migrate. 
This simple and reproducible assay is commonly used to measure the cell 
migration capability of cells. Cells were grown to confluence and “wound” were 
introduced by scratching the cells with a pipette tip. Through this assay we could 
show the directional migratory response of the cells. As shown in Figure 3.7A, 15 
hr after the scratching, FAT10 overexpressing cells (FAT-A and FAT-B) can 
migrate faster in compared to WT cells.  
Another central feature of invasion and metastasis is cell adhesion. Figure 
3.6B showed that a greater number of adherent cells in FAT10 overexpression 
cells in comparison with WT cells. This indicated that FAT10 promoted cell 
adhesion. Moreover, enzyme-linked immunosorbent assay (ELISA) showed an 
increased in matrix metalloproteinase 9 (MMP-9) concentration by at least 4 fold 
in FAT10 overexpressing cells. MMP-9 is known for its ability to degrade type IV 
collagen that is present in the basal membrane. Higher concentration of MMP-9 in 
FAT10 overexpressing cells facilitated the degradation of the components of the 
ECM with a higher efficiency, which again showed that FAT10 overexpression 
could drive these colorectal HCT116 cells to be more invasive (Figure 3.7 C).   
 




              
 B. 
 
Figure 3.6 FAT10 promotes cell invasion. A. Invasion profiles of WT HCT116 
and FAT10 stably overexpressing cells. Cells were assayed for invasion using 
Transwell inserts coated matrigel for 16 hours, after which the invaded cells 
were stained and quantified. FAT10 overexpression in HCT116 significantly 
increased cell invasion compared to WT cells. Representative pictures of the 
invaded cells are shown below the graphs.  The data shown is representative of 3 
biological repeats. B. Rhodamine-Phalloidin staining to show actin cytoskeleton 
profiles of cells. The cells were seeded on poly-L-lysine-coated 6-well plate, 
allowed to adhere for 24 hours and stained with rhodamine-conjugated phalloidin 
to visualize filamentous actin. Pictures display a representative set of experiments 
(X 400). Scale bar represents 20µm. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 3.7 
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Figure 3.7 FAT10 supports cell invasion, migration and adhesion. A. Cell migration of 
HCT116 assessed by scratch-wound healing assay. Confluent HCT116 cell monolayers 
were scratched and monitored for 15 hours. The direction of cell migration is showed by 
the arrows. The furthest distance from HCT116 cells migrated from the edge of scratch 
was measured in 5 random fields (X200), an inverse correlation of the distance of gap and 
migration was performed. The graphs show the migration index relative to WT, based on 3 
independent experiments. Representative pictures of the invaded cells are shown above the 
graphs. B. Profiles of the adhesive properties of WT HCT116 and FAT10 overexpressing 
cells (FAT-A and FAT-B). Cells were seeded in collagen IV-coated wells and allowed to 
adhere for 2 hours, after which adhered cells were quantified in 5 random fields (X200). 
Graph shows the mean and standard error (SE) of the number of adhered cells. Graph 
showing a significant higher number of adherent cells in FAT10 stable overexpressing 
HCT116 cells adhered to collagen. The data shown is representative of 3 experiments. C. 
MMP-9 concentration measured by ELISA from WT and FAT10 overexpressing cells. 
FAT10 drives a significantly higher concentration of MMP-9. 
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3.8 FAT10 supports tumor growth in nude mice 
It is important to address whether the oncogenic properties of FAT10 can also be 
recapitulated in vivo. To address this question, WT and FAT10 overexpressing 
cells were subcutaneously injected into the left and right flanks of nude mice, 
respectively. Here, for the first time we were able to show that subcutaneous 
injection of FAT10 overexpressing HCT116 cells promoted tumor growth as 
shown by a bigger tumor size in Figure 3.8A. A quantitative measurement of 
tumor weight after 3 weeks of injection as well as progressive measurement of 
tumor size was performed using an analytical precision balance and digital caliper, 
respectively. As shown in the graph in Figure 3.8B, C, mice injected with FAT10 
overexpressing cells has a heavier tumor weight as well as a bigger tumor size in 
comparison with WT HCT116 cells. Collectively, these in vitro and in vivo results 
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Figure 3.8 FAT10 supports tumor growth in nude mice. A. WT and FAT10 
stably overexpressing cells were subcutaneously injected into the right and left 
flank of at least 6 nude mice (n=6), respectively. 3 weeks after the injection, mice 
were sacrificed and tumors were isolated. FAT10 overexpression in HCT116 
significantly increased the tumor growth in compare to WT. B. Measurement of 
tumor weight from each group of injected cells. (n=6 in each group). Data is 
expressed as mean+s.e. *p<0.05; **p<0.01. C. Tumor size measured every week 
with digital caliper (n=6 in each group). Tumor volume was calculated using the 
formula 0.5 x a x b
2
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3.9 Identification of specific binding sites responsible for FAT10 and Mad2 
interaction 
3.9.1 Identification of the specific Mad2 binding sites on FAT10 using Nuclear 
Magnetic Resonance (NMR) 
Our collaborator, A/P Song Jianxing employed a Nuclear Magnetic Resonance 
(NMR) study to map Mad2 interacting sites on FAT10 upon its binding with 





N-HSQC (Heteronuclear single quantum coherence) spectra. 
An HSQC spectrum is like a “fingerprint” of the protein because each peak is 
associated to an NH group of each amino acid residue. The chemical shift in both 
nitrogen (15N) and proton (1H) is sensitive to the chemical environment of the two 
nuclei. Examination of the HSQC spectra of 
15
N-labelled FAT10 alone, will give a 
spectra of FAT10 without Mad2. The HSQC spectra were then obtained again but 
now upon addition of Mad2. Addition of Mad2 into 
15
N-labeled FAT10 resulted in 
a chemical shift in HSQC spectrum, which can be observed by a change in the 
peaks observed in HSQC spectrum. Since every peak corresponded to an amino 
acid in FAT10 protein, it is thus possible to specifically map out the specific Mad2 
interaction regions within FAT10. Mad2 was found to bind at two specific regions 
in domain 1 of FAT10 protein. We would like to apologize that the exact sequence 
of the Mad2 interaction regions in FAT10 cannot be revealed in this thesis as we 
are only in the process of getting it patented.  
Based on the result from this NMR study, we then performed mutagenesis 
study of the predicted specific regions were mutated using fusion-PCR 
mutagenesis method. We created five different FAT10 mutants as follows (Figure 
2.2): the first mutant (FAT-mutant-Left/FAT-mL) consists mutations at region I of 
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Mad2 interaction regions within FAT10 The second mutant (FAT-mutant-
Right/FAT-mR) consists of mutations at region II of Mad2 interaction regions 
within FAT10. The third mutant is a combination of mutations from FAT-mL and 
FAT-mR, whereby we mutated all the NMR-predicted amino residues that are 
important for Mad2 binding on FAT10. We named this mutant FAT-mutant-Left-
Right/FAT-mLR. The fourth mutant is FAT-Lys, where we mutated the entire 
Lysine residue of FAT10 from Lysine (K) to Arginine (R), which might be 
important for poly-FATylation. Finally, the fifth mutant is FAT-Gly with mutated 
double-glycine residue at C-terminal of FAT10 protein that is important for 
FAT10-covalent conjugation with its substrates.   
3.9.2 Generation of FAT10 and FAT10 stable mutants 
FAT10 and FAT10 stable mutants were generated by transfection of pcDNA3 
plasmid carrying wild type FAT10 or FAT10 mutants (FAT-mL, FAT-mR, FAT-
mLR, FAT-Lys, and FAT-Gly) and selected with G418 as described in chapter 
2.1.2. Here, we show that wild type FAT10 as wells as its mutant derivatives are 
indeed stably expressed to comparable levels at the protein level (Figure 3.9). 
Western blot analysis from the whole cell lysate of these stable cell lines were run 
through SDS-PAGE gels and detected using FAT10 specific antibody. These 
mutants were generated to validate the FAT10-Mad2 interaction site, identified 









Figure 3.9 FAT10 protein expressions in FAT10 stable clones and its mutant 
derivates. Western blot analysis from the whole cell lysate of the FAT10 stable 
and FAT10 mutants cells (FAT-mL, FAT-mR, FAT-mLR, FAT-Lys, and FAT-
Gly). Western blot shows that we successfully generated a stable cell lines that 
overexpressed wild type FAT10 or FAT10 mutants.  
 
 
3.9.3 Identification of the specific Mad2 binding sites on FAT10 using co-
Immunoprecipitation method 
Using all the generated FAT10 mutant stable clones that have been mentioned 
above, we then performed co-immunoprecipitation experiment to validate, which 
Mad2 interaction regions within FAT10 is important for FAT10-Mad2 binding. As 
shown in Figure 3.10, we found that only FAT-m-LR abolished the binding 
between FAT10 and Mad2, whereas FAT-mL and FAT-mR did not abolish the 
binding between FAT10 and Mad2. To address whether these sites bind 
specifically to Mad2 and not other interacting proteins of FAT10, co-
Immunoprecipitation was also performed with other reported interaction proteins 
of FAT10 using WT, FAT10-overexpressing cells and its stable mutants. SDS-
PAGE-Western blotting was performed and blots were probed with various 
antibodies listed in table 2.1 (Mad2, p62, NUB1L, UBA6, and HDAC6). 
 







Figure 3.10 Abolishment of Mad2 binding on FAT10 observed in FAT-mLR 
A. Pictorial diagram of mutations generated in FAT10 protein, which are important 
for the binding with Mad2. B. Co-IP-Western blot analysis of interactions between 
FAT10, Mad2, p62, NUB1L, UBA6, and HDAC6. Mad2, p62, NUB1L, UBA6, 
and HDAC6 are proteins that have been reported to have an interaction with 
FAT10. HCT116 cells were transfected with pcDNA3 plasmid carrying FAT10, 
FAT10 mutants (FAT-mL, FAT-mR, and FAT-mLR), FAT10 Lysine mutant 
(FAT-Lys), or FAT10 Glysine mutant (FAT-Gly). Total cell lysates of WT, 
FAT10 overexpressing, and FAT10 mutants (FAT-mL, FAT-mR, FAT-mLR, 
FAT-Lys, FAT-Gly) were treated with RNase-A and incubated with anti-FAT10 
antibody conjugated to agarose beads. The immunoprecipitates were analyzed by 
SDS-PAGE-Western blotting method and probed with the specific antibodies 
(MAD2, NUB1L, p62, UBA6, HDAC6). p16 served as loading control and 
nonspecific control. 
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We selected to perform the co-IP with these antibodies, because these proteins 
have been previously reported to interact with FAT10 (Table1.3). Indeed, we 
found that FAT-mLR was specific only for Mad2 and FAT10 binding as 
abolishment of these sites did not affect the binding of FAT10 with its other 
interaction partners like UBA6 (FAT10-E1 activating enzyme), NUB1L, p62, and 
HDAC6 (Figure 3.10B). On the other hand, FAT-Gly mutant is unable to bind to 
UBA6 and p62, because these proteins bind covalently to FAT10 through the 
glycine residue (Aichem et al 2012b, Pelzer and Groettrup 2010). Other non-
covalently conjugated interaction partners like HDAC6, and NUB1L were also not 
affected by the mutation at these FAT10`s residues (Kalveram et al 2008, 
Schmidtke et al 2006). We used p16 as a loading and random control.  
3.9.4 Identification of disruption of FAT10 and MAD2 binding using in situ 
Proximity Ligation Assay (PLA) method 
To strengthen our previous results from co-IP, we used another method to 
detect protein-protein interaction between FAT10 and Mad2 as well as other 
FAT10’s interaction partners. This method is called in situ proximity ligation assay 
(PLA). Using in situ PLA allowed us to detect protein-protein interaction directly 
from the cells; therefore it is less tedious than using co-Immunoprecipitation. One 
can also visualize the interaction at single cell level.  
In concordance with co-Immunoprecipitation results mentioned in the 
previous section, in situ PLA also demonstrated that the mutated amino acid 
residues in FAT-mLR cells was the specific site for FAT10 and Mad2 binding and 
not for the other reported FAT10 interaction partners (Figure 3.11). Disruption of 
these binding sites abolished the binding of Mad2 on FAT10 only. As negative 
control, we used p16 plus FAT10 antibodies to probe the FAT10 overexpressing 
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HCT116 cells. As mentioned above, to validate the specificity of this PLA assay, 
we probed the FAT10 overexpressing cells with only one antibody (FAT10 or 
Mad2 antibody) or no antibody. This validation allowed us to ascertain that PLA’s 
results were reliable, because PLA signal was only observed, when two proteins 
interacted with each other, otherwise no signal were detected. In this experiment, 
WT-HCT116 cells, wild type FAT10 overexpressing cells, as well as various 
FAT10 mutant cells (FAT-mL, FAT-mR, FAT-mLR, FAT-Lys, and FAT-Gly) 
were used. To test that these amino acid residues were the specific regions that 
were responsible for FAT10 and Mad2 binding, interaction between FAT10 with 
its other protein interaction partners such as HDAC6, p62, NUB1L, and UBA6 
were also investigated. Collectively, based on two different experiments with two 
different methods (co-Immunoprecipitation and in situ PLA), we demonstrated that 
only FAT-mLR abolished FAT10 and Mad2 binding. In summary, our results 
demonstrated the specific binding regions of Mad2 on FAT10. These regions only 
prevented the binding of FAT10 to Mad2 but not to other proteins reported to 
interact with FAT10. Hence, altering these amino acid residues of FAT10 is 
unlikely to alter other cellular functions of FAT10.  





Figure 3.11 In situ PLA results showing Mad2 binding on FAT10 was 
abolished in FAT-mLR mutants. In-situ-PLA analysis of WT, FAT10 
overexpressing, and its derivatives mutants HCT116 cells (FAT-mL, FAT-mR, 
FAT-mLR, FAT-Lys, and FAT-Gly). Red fluorescence signals represent an 
interaction detected by the assay (positive PLA signal) targeted by two primary 
antibodies. In this assay, interaction of FAT10 with 5 different proteins (MAD2, 
p62, UBA6, HDAC6, and NUB1L) was analyzed. All cells were counterstained 
with DAPI to visualize nuclei of the cells. As negative control (bottom right 
panel), FAT10 and p16 antibody were used, because FAT10 did not interact with 
p16. In addition, a single antibody (FAT10/MAD2 only) was used to check the 
specificity of PLA. No Antibody refers to control assay, where cells where 
incubated with only secondary antibodies. 
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3.10 Specific mutations of FAT10 and MAD2 binding sites attenuate cell 
proliferation of HCT116 cells 
Having identified the specific binding regions between FAT10 and Mad2, 
which plays an important role in aneuploidy and tumorigenesis, we would also like 
to know whether disruption of these binding regions would affect the cellular 
function of the cells such as its cell proliferation. Therefore, we measured the cell 
proliferation rate of WT, two FAT10 overexpressing stable clones, FATi stable 
clone, FAT-mL, FAT-mR, and two FAT-mLR stable clones using WST-1 cell 
proliferation assay. Interestingly, we found that FAT-mLR mutants have 
significantly lower cell proliferation rate by at least 3 fold in comparison with 
FAT10 overxpressing stable clones and by at least 1.5 fold in compare with WT 
HCT116 cells (Figure 3.12A). In addition, as shown in Figure 3.12B, FAT-mLR-A 
(27.050.31h) and FAT-mLR-B (26.030.40h) have a longer cell doubling time in 
compare with FAT10 overexpressing cells (FAT-A: 19.830.26h, FAT-B: 
19.310.21h) or WT HCT116 cells (23.420.25h). The cell proliferation rate and 
doubling time of FAT-mLR mutants is almost similar with FAT10 knockdown 
stable cells (FATi). Therefore, it shows that the disruption of FAT10 and MAD2 
binding abated the cell proliferation of colorectal cancer cells HCT116.   
3.11 Disruption of binding between FAT10 and Mad2 curtailed the 
anchorage-independent growth of HCT116 cells 
Since FAT-mLR mutants could slow down the cell proliferation, we also 
further investigated the effect of these mutants in supporting anchorage-
independent growth in soft agar. Previously, we demonstrated that FAT10 
augmented the anchorage-independent growth of colorectal cancer HCT116 cells 
(Figure 3.3). 







Figure 3.12 Disruption of FAT10 and MAD2 binding sites via mutations of its 
binding sites decreased cell proliferation of HCT116 cells. A. Cell proliferation 
rate of WT, FAT10 overexpressing stable cells (FAT-A, FAT-B), FAT10 mutants 
(FAT-mL, FAT-mR, and FAT-mLR) and FAT10 stable knockdown cells (FATi). 
Cells were grown in 96-well plate for 108 hours and cell proliferation was 
measured using calorimetric WST-1 assay every 24 hours. B. Doubling time of 
WT, FAT10 overexpressing cells, and its mutant derivates. Doubling time is 
calculated using this following formula (doubling time = (ln(2)/ ln(Ct/C0))*t). Data 
is represented as mean+s.e. from 3 biological repeats. **denotes statistical 
significance p-value <0.01 compared with WT. ## denotes statistical significance 
at p-value<0.01 compared with FAT10 overexpressing cells. 
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Therefore, we then further investigated, whether the disruption of FAT10 and 
Mad2 binding regions has an effect on the ability of HCT116 colorectal cancer 
cells to grow and form colonies in soft agar. The ability of cells to grow in a 
condition without adherence into a solid substrate shows one of the features of 
malignant cells. Remarkably, mutation at region I and region II of Mad2 binding 
regions within FAT10 (FAT-mLR) significantly attenuated the ability of HCT116 
cells to form colonies in soft agar (p<0.001) compared to FAT10-overexpressing 
cells. Figure 3.13 shows that FAT-mLR mutants have 8.33.5 colony numbers in 
comparison with FAT10 overexpressing cells that have 471.715.5 colony 
numbers. In addition, mutations at either site of FAT10 and Mad2 binding sites 
(FAT-mL/FAT-mR) have slightly decreased the formation of colonies in soft agar 
in compare to FAT10-overexpressing cells (FAT10). However, similar numbers of 
colonies were observed in FAT-mL (130.311.9 colonies) and FAT-mR (74.09.5 
colonies) as well as WT HCT116 cells (125.716.2 colonies). Despite its lower 
colony numbers, mutations at only one Mad2 regions within FAT10 (FAT-mL and 
FAT-mR) were still showed a higher colony numbers compared to FAT-mLR 
cells, where both Mad2 regions within FAT10 have been mutated (FAT-mLR). 
These results again further strengthened our notion that targeting the specific 
binding regions between FAT10 and Mad2 reduced the cell malignant 
transformation.  
3.12 Interruption of FAT10 and MAD2 binding increases its cytotoxic induced 
cell death 
Having demonstrated the importance of disruption of FAT10 and Mad2 
binding in cell proliferation, we next examined the apoptotic profiles of WT, 





Figure 3.13 Disruption of FAT10 and MAD2 binding reduces the anchorage-
independent growth of HCT116 cells in soft agar. The graph shows the total 
number of colonies formed in soft agar. WT, FAT10 overexpressing cells, FAT-
mL, FAT-mR, and FAT-mLR stable clones were seeded in 6-well plate. After 3 
weeks soft agar were stained and colonies were counted. The pictures is a 
representative sets from 1 experiment. Data is represented as mean+s.e. from 3 
biological repeats. **denotes statistical significance p-value <0.01 compared with 
WT. ## denotes statistical significance at p-value<0.01 compared with FAT10 
overexpressing cells. ### denotes statistical significance at p-value<0.001 














Figure 3.14 Interference of FAT10 and MAD2 binding increases the 
percentage of cell death. A. Representative set of flow cytometry pictures from 
WT, FAT10 overexpressing stable cells (FAT-A, FAT-B), and FAT10 mutant cells 
(FAT-mL, FAT-mR, FAT-mLR-A, FAT-mLR-B) stained with FITC-Caspase3. B. 
Percentage of apoptotic cells described in A from 3 independent experiments. The 
bar chart shown in the graph is mean±s.e. ** denotes p-value<0.01 compared to 
WT HCT116 cells, ## denotes p-value<0.01 compared to FAT10 overexpressing 
cells (FAT-A, FAT-B). 
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wild type FAT10, and its mutants FAT10 stable cells upon Camptothecin-induced 
cell death. Previously, in Chapter 3.5, we have shown that FAT10 overexpression 
increased cell survival upon cytotoxic induced cell death. Therefore, we also 
validated, whether FAT10’s pro-survival ability, could be reverted back upon the 
disruption of MAD2 binding regions within FAT10 protein.  Caspase 3 staining 
followed by flow cytometry analysis was performed to check the effect of the 
disruption of FAT10 and Mad2 binding sites on cell survival.  
Approximately 17% increase in apoptotic cells was observed, when both 
Mad2 binding sites on FAT10 protein were mutated (Figure3.14 B). As shown, 
FAT-mLR-A (20.36±1.66%) and FAT-mLR-B (22.22±1.59%) showed a high 
percentage of apoptotic cells comparable to WT cells (21.38±1.47%) upon 
cytotoxic treatment. In agreement with our previous finding, we once again 
demonstrated that FAT10 overexpression  (FAT-A: 3.35±0.38%, FAT-B: 
1.99±0.69%) promoted cell survival. Interestingly, mutations at one region of 
Mad2 interaction regions within FAT10 (FAT-mL: 4.19%±0.27%, FAT-mR: 
3.11±0.89%) did not significantly increase the rate of apoptosis upon cytotoxic 
treatment. Hence, FAT-mL and FAT-mR cells were able to evade apoptosis.  
3.13 Disruption of FAT10 and Mad2 binding abrogates cell invasiveness of 
HCT116 cells 
The gain of invasive and migratory capabilities of FAT10 overexpressing 
cells, which has been showed previously in Chapter 3.6, were reduced by the 
disruption of FAT10 and Mad2 binding. Through fusion-PCR-mutagenesis 
experiments, we mutated Mad2 interaction regions within FAT10 protein. As 
shown in Figure 3.15A, only FAT-mLR mutants reduced the ability of HCT116 
cells to migrate and invade the matrigel-coated transwell membrane by at least  
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Figure 3.15 The importance of FAT10 and MAD2 binding in cell invasion. A. 
Migration and invasion profile of WT, FAT10 overexpressing cells and its mutant 
derivates (FAT-mL. FAT-mR, FAT-mLR). The pictures show the migrated cells 
after 24 hours taken under the microscope with 40x magnification after staining 
with Diff Quick. The graph shows the number of migrated cells, which represents 
the degree of invasiveness of these cells in vitro. Data is represented as mean+s.e. 
(*p<0.05, **p<0.01 compared to WT, #p<0.05, ###p<0.001 compared to FAT10 
overexpressing cells) B. Actin cytoskeleton profiles in HCT116 cells. The cells 
were seeded on poly-L-lysine-coated 6-well plate, incubated for 24 hours for the 
cells to adhere and stained with rhodamine-conjugated phalloidin to visualize 
filamentous actin. Pictures are shown as representative sets from at least 3 
independent experiments.  
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compared to FAT10-overexpressing cells. However, mutations of amino acid 
residues only at region I (FAT-mL) or region II (FAT-mR) of Mad2 interaction 
regions within FAT10 protein attenuated the invasiveness of HCT116 cells by 2 
fold and 1.5 fold, respectively in comparison with FAT10 overexpressing cells. 
Nevertheless, only the invasiveness of FAT-mLR was significantly decreased 
compared to wild type HCT116 cells.  
The ability of cells to invade and migrate requires dynamic actin cytoskeletal 
remodelling and the formation of protrusive structures. Hence, we investigated the 
actin cytoskeleton features of the cells using rhodamine-phalloidin staining. In 
general, immunofluorescence indicated that only FAT-mLR and WT HCT116 
cells did not show enriched lamellipodia structures unlike the FAT10- 
overpressing, FAT-mL, and FAT-mR stable cells. The disappearance of 
lamellopodia structures, which were required for active cytoskeletal turnover at the 
edge of migrating cells, indicated that FAT-mLR mutant was less invasive. 
Consistently, with our previous findings disruption of FAT10 and Mad2 binding 
were not only diminished the cell proliferation and cell survival of rate, but it also 
reduced the cell invasion.  
3.14 Cell adhesion and migration is decelerated by the disruption of FAT10 
and Mad2 binding  
Having shown that FAT-mLR reduced cell proliferation, cell survival, and cell 
invasion rate of HCT116 cells. Further, effect of these FAT10 stable mutants 
(FAT-mL, FAT-mR, and FAT-mLR) on cell adhesion to an extracellular matrix 
were investigated, since cancer metastasis tumors that spread through the 
circulatory system capitalize mechanisms of cell adhesion to establish new tumors.  
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Figure 3.16 Deceleration of cell adhesion and migration caused by disruption 
of FAT10 and MAD2 binding. A. Cell adhesion profile of WT, FAT10 
overexpressing cells (FAT-A, FAT-B), and FAT10 mutants (FAT-mL, FAT-mR, 
FAT-mLR-A, FAT-mLR-B). B. The migration ability of WT, FAT10 
overexpressing cells, and its mutant derivates after introduction of “wound”. Data 
is expressed in means.e from three independent experiments. 
(*p<0.05,**p<0.01,***p<0.001 compared to WT; ##p<0.01, ###p<0.001 
compared to FAT10 overexpressing cells). 
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 As shown, Figure 3.16A shows less adherent cells in FAT-mLR mutants 
compared to FAT10-overexpressing, FAT-mL, and FAT-mR stable cells. Scratch-
wound-healing assay to check the migration ability of these FAT10 mutant cells 
were also performed. The closure of the “wound” measured the migration ability 
of these cells. As shown in Figure 3.16B, 15 hours post ”wound” introduction, 
FAT-mLR has a slower migration ability to close the “wound-gap” compared to 
FAT10-overexpressing cells, since the “wound” in FAT10-overexpressing cells 
was almost closed. Consistent with the results from transwell invasion assay and F-
actin staining, FAT-mL and FAT-mR mutants showed a similar distance of 
“wound-gap closure” as FAT10 overexpressing cells. Taken together, these results 
conferred the importance of FAT10 and Mad2 binding in cell invasion, adhesion as 
well as migration. Thus, targeting this specific interaction between FAT10 and 
Mad2 abrogated the invasion and migration of colorectal cancer HCT116 cells. 
3.15 Disruption of FAT10 and Mad2 binding prevents cells from escaping the 
mitotic cell arrest. 
In our previous finding, we found that overexpression of FAT10 led the cells 
to escape from mitotic cells arrest and became multinucleated upon prolong 
mitotic arrest. Therefore, to address the question, whether disruption of FAT10 and 
Mad2 binding help the cells to escape mitotic cell arrest, we treated WT, wild type 
FAT10-overexpressing cells and mutants FAT10 stable cells (FAT-mL, FAT-mR, 
FAT-mLR, FAT-Lys, and FAT-Gly) with 200ng/ml nocodazole for 8h, prior the 
nocodazole treatment we synchronized the cells at G1/S phase using 3mM 
thymidine for 17h. Post 8h of nocodazole treatment, mitotic-specific antibody 
(MPM2) was used to stain specifically mitotic cells,  
 





Figure 3.17. A reduce level of cells escaping from mitotic arrest observed in 
FAT-mLR mutants. Representative histograms showing the fluorescence-
activated cell sorting profile of cells probed with MPM-2 antibody. The graph 
shows the average percentage of mitotic cells with MPM-2 positive staining from 
3 independent experiments. All error bars show standard error (s.e.) of the mean. 
(**p-value<0.01 compared to WT, and #p-value<0.05 compared to FAT10 
overexpressing cells). 
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followed by Alexafluor488 staining as dye that can be detected by FACS and at 
the last step these cells were analyzed using FACS Calibur flow cytometer.  
As shown in Figure 3.17 approx. around 10% more WT and FAT-mLR cells 
were arrested at mitosis compared to FAT10-overexpressing, FAT-mL, and FAT-
mR cells. These results suggest that disruption of FAT10 and Mad2 binding 
reverted back the ability of these cells to escape the mitotic arrest. However, 
mutations only at one region of Mad2 interaction regions within FAT10 (FAT-mL 
and FAT-mR) helped the cells to escape from the mitotic arrest compared to WT 
and FAT-mLR cells. Interestingly, mutation of all the lysine residues (FAT-Lys) or 
double-glycine residues (FAT-Gly) did not enhance the ability of these cells to 
escape from mitotic cell arrest.  
3.16 Disruption of FAT10 and Mad2 binding prevents aneuploidy 
Based on our previous study, we found that FAT10 overexpression induced 
numerical chromosomal instability (CIN). Therefore, we further examined, if 
disruption of FAT10 and Mad2 binding can prevent CIN. WT, wild type FAT10 
and mutants FAT10 that were stably expressed in HCT116 cells (FAT-mL, FAT-
mR and FAT-mLR) were cultured for approx. 50 passages (150 doubling time), 
before karyotyping analysis were performed. A relatively stable karyotype was 
observed from WT HCT116 cells. As shown in Figure 3.18B, majority of WT 
HCT116 cells (84%) have 40-49 chromosomes/cell. Only a smaller percentage of 
cells were observed to have more than 80-90 chromosomes/cell and none of the 
WT cells contained more than 100 chromosomes/cell. Similar karyotype trends as 
WT cells were observed in FAT-mLR mutant cells, whereas FAT10 
overexpressing cells, FAT-mL and FAT-mR mutants (71%, 68% and 65%, 
respectively) were in majority observed to  










Figure 3.18 Complete disruption of FAT10 and MAD2 binding prevents 
aneuploidy. A. Representative pictures of chromosome morphology from WT, 2 
stable clones of FAT10 overexpressing cells (FAT-A, FAT-B), and its mutant 
derivatives stable cells (FAT-mL, FAT-mR, FAT-mLR-A, Fat-mLR-B). 
Metaphase spread from FAT-mLRA and FAT-mLRB displaying a normal sister 
chromatid separation with completely condensed chromosome unlike FAT-A, 
FAT-B, FAT-mL, and FAT-mR. B. Table showing the karyotyping profile of cells 
based on its chromosome numbers.  
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carry 80-90 chromosomes per cell. Thus, it suggests that disruption of FAT10 and 
Mad2 binding prevented the cells to become aneuploid.  
Through karyotyping experiment, not only numerical chromosomal instability 
were observed, but interestingly, altered chromosome morphology were also 
observed in FAT10-overexpressing, FAT-mL and FAT-mR mutants stable cells. 
As evidence, Figure 3.18A shows the abnormal chromosome morphology, where 
the sister chromatid separation to have incomplete condensed chromosome in 
FAT10 overexpressing, FAT-mL and FAT-mR cells. Incomplete condensed 
chromosome morphology was not observed in FAT-mLR mutants and WT 
HCT116 cells. As shown in Figure 3.18A, normal condensed chromosome 
morphology during metaphase looked like a ribbon, whereas altered chromosome 
morphology looked like a strand without a proper separation of chromosome arms. 
Taken together, these data revealed that FAT10-overexpressing, FAT-mL and 
FAT-mR exhibited premature sister chromatid separation with incomplete 
condensed chromosome and more aneuploid cells. This phenomenon can be 
reverted by the disruption of FAT10 and MAD2 binding as shown by the normal 
karyotype profile of FAT-mLR mutant cells. 
3.17 Disruption of FAT10 and Mad2 binding diminishes tumor growth in 
xenograft nude mice model 
In order to reaffirm the importance of the disruption of FAT10 and Mad2 
binding in affecting the cellular phenotypes such as cell proliferation obtained 
from the in vitro study. Next, we performed an in vivo study, where we injected 
WT, FAT10-overexpressing cells, and FAT10 mutants cells (FAT-mL, FAT-mR 
and FAT-mLR) subcutaneously into the left and right flank of nude mice. In this 
experiment, four different groups of mice were used as follows: WT vs. FAT10  





Figure 3.19 Abolishing FAT10 and MAD2 binding abates tumor growth in 
nude mice model. The representative set of pictures above shows the tumor 
growth of WT, FAT10 overexpressing (FAT10), FAT-mL, FAT-mR, and FAT-
mLR stable cells injected subcutaneously. The graph shows the tumor weight of 6 
nude mice measured with precision balance, 3 weeks after the subcutaneous 
injection into the nude mice. The middle picture shows the tumors isolated from 
the nude mice. Data is expressed means.e. (**p-value<0.01,***p-value<0.001 
compared to WT, and ###p-value<0.001 compared to FAT10 overexpressing 
cells). 
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overexpressing cells, FAT10 overexpressing cells vs. FAT-mL mutants, FAT10 
overexpressing cells vs. FAT-mR mutants, and FAT10 overexpressing cells vs. 
FAT-mLR mutants. In each group six mice were used. 
In accordance with our previous finding, where we overexpressed FAT10, we 
once again observed a greater promotion of tumor growth of FAT10-
overexpressing stable cells in comparison with WT HCT116 cells in nude mice 
model. Notably, as shown in Figure 3.19, we also found that FAT-mLR stable 
mutant cells have an impaired tumor growth compared to FAT10-overexpressing 
cells. Remarkably, these FAT-mLR mutant cells have significantly smaller tumors 
than WT HCT116 cells. However, FAT10 mutants harboring only one mutated 
Mad2 binding regions within FAT10 (FAT-mL and FAT-mR) only showed a 
marginal decrement of tumor growth in comparison to FAT10-overexpressing 
cells. An augmented tumor growth in these mutant cells (FAT-mL and FAT-mR) 
was still observed compared to WT, although one Mad2 binding regions within 
FAT10 were mutated. These results clearly suggest that we need to abolish both 
binding regions of Mad2 interaction regions within FAT10 in order to abate the 
tumor growth. Therefore, based on our in vivo study, FAT10 and Mad2 binding 
played an important role in tumorigenesis, and the interference of these binding 
negated the pro-survival role of FAT10. 
3.18 FAT10 overexpression phenocopies Mad2 knockdown effects to escape 
from mitotic cell arrest.  
Previously, our laboratory has reported that FAT10 overexpression reduced 
the localization of Mad2 at the kinetochores during mitosis, which led to 
abbreviation of mitotic duration and aneuploidy. Therefore, in order to validate  
 




A.                                                                    B. 
    
   
 
Figure 3.20 FAT10 overexpression or MAD2 knockdown can help the cells to 
escape from mitotic arrest A. The Histogram (Upper left panel) shows the 
representative of FACS data analyzed with WinMDi2.9 software. WT, and FAT10 
overexpressing cells were used in this experiment and two different MAD2siRNA 
(MAD2iA, and MAD2iB) as well as scramble siRNA (CTRi). The graph (bottom 
panel) shows the percentage of mitotic cells that positively stained with mitotic 
specific antibody (MPM-2). Data is represented as means.e. from 3 independent 
experiments. ** denotes p-value <0.01, *** denotes p-value <0.001 compared to 
WT cells. B.Western blot analysis of MAD2 and FAT10 protein expression in WT 
and with a long term treatment of MAD2siRNA or scramble siRNA (CTRi) and 
FAT10-overexpressing cells to check the efficiency of MAD2 knockdown and 
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whether Mad2 knockdown or FAT10 overexpression exerts a similar effect on 
mitotic escape and aneuploidy, we employed siRNA knockdown against Mad2. 
WT and FAT10- overexpressing stable HCT116 cells were repeatedly transfected 
with two different MAD2 siRNA (MAD2iA, MAD2iB) or scrambled siRNA 
(CTRi) within a period of at least 20 passages (~100 doubling times). The 
introduction of these siRNAs over a prolonged period will allow us to examine the 
effect of Mad2 knockdown on these colorectal cancer HCT116 cells. After 20 
passages, these cells were then synchronized with 3mM of thymidine, followed by 
nocodazole treatment to arrest the cells at mitotic phase. These cells were then 
stained with mitotic specific antibody (MPM-2), which is a marker of mitosis, and 
analyzed using fluorescence cell sorting (FACS). 
 As shown in Figure 3.20A, either FAT10 overexpression or Mad2 
knockdown were found to help the cells to escape from mitotic arrest. This result is 
in agreement with our previous findings, which showed that FAT10 interacted 
with Mad2, and induced Mad2 delocalization from the kinetochores during pro-
metaphase. 
Validation of Mad2 and FAT10 protein expression level on cells used for 
this experiment and subsequent experiments is showed in Figure 3.20B by 
performing Western blot using the cell lysates. Western blot analysis showed an 
efficient knockdown of Mad2 over a long-term treatment of cells with 
MAD2siRNA treatment. WT and FAT10-overexpressing cells treated with 
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3.19 Reduced Mad2 expression or FAT10 overexpression promotes 
aneuploidy in HCT116 cells 
Having demonstrated similar phenotypes between FAT10 overexpression 
and Mad2 knockdown in escape of mitotic cell arrest, we further investigated, 
whether the proportion of aneuploid cell population in FAT10-overexpressing cells 
is similar to that of Mad2-knockdown cells. Therefore, we utilized the WT and 
FAT10- overexpressing cells that has been treated with MAD2 siRNA over a long-
term period (20 passages) for analysis of the number of chromosomes in cells.  
Consistent with our previous findings in Chapter 3.18, we also found that FAT10 
overexpression or reduction of Mad2 level resulted in increased proportion of 
aneuploidy cells (Figure 3.21A, B). In addition, around 72% of FAT10- 
overexpressing cells or 70% of Mad2-knockdown cells alone are having 80-89 
chromosomes per cell. In contrast, 81% of WT cells have 40-49 chromosomes per 
cell. Thus, this further strengthens our previous data, which showed that FAT10 
overexpression led to a reduction of Mad2 localization at the kinethochore during 
mitosis. There is no statistical difference between the number of chromosomes in 
















Percentage of cells(%) 
WT WT+CTRi WT+MAD2iA WT+MAD2iB FAT10 
30-39 3.8 5.2 2.4 3.5 2.5 
40-49 81.6 80.4 15.7 17.2 11.1 
50-59 3.7 4.6 2.3 1.5 1.7 
60-69 2.4 1.2 1.8 1.8 1.2 
70-79 3.8 2.6 3.9 5.3 9.6 
80-89 3.3 4.8 69.8 68.0 72.6 
90-99 1.4 1.2 0.2 1.1 0 








Figure 3.21 FAT10 overexpression or reduction of Mad2 level resulted in 
increased proportion of aneuploid cells. A. Table showing the profile of 
chromosome number in WT, WT+CTRi, WT+MAD2iA, WT+MAD2iB, and 
FAT10-overexpressing cells. Two different MAD2siRNAs were utilized in this 
experiment. B. Representative graph showing the chromosome number per cell of 
WT, WT+MAD2iA, and FAT10-overexpressing stable cells (FAT10) obtained 
from karyotyping experiments. Data is expressed in means.e. * denotes p-
value<0.05, ** denotes p-value <0.01. 
Chapter 4 Discussion 
 94 
Chapter 4 Discussion 
 
4.1 Fundamental background of this thesis 
FAT10 overexpression was found in several different types of cancers, such as 
colorectal cancer, hepatocellular carcinoma, stomach cancer, and gynecological 
cancer (Lee et al 2003, Lim et al 2006). Additionally, pro-inflammatory cytokines 
TNF and IFN synergistically induced FAT10 overexpression in colon and liver 
cancer cell line (Lukasiak et al 2008b). Taken together, these studies suggested 
that FAT10 might play a role in tumorigenesis. A study by Liu et al reported non-
covalent interaction between FAT10 and a mitosis spindle checkpoint Mad2 (Liu 
et al 1999b). Based on this report, we then examined the role of FAT10 and Mad2 
interaction in tumorigenesis. Mad2 is an important mitotic spindle checkpoint and 
its deregulation is widely known to cause improper chromosome segregation leads 
to aneuploidy, one of the hallmarks of cancers (Hanahan and Weinberg 2011). 
Therefore, this interaction suggests a role of FAT10 in the regulation of cell 
division. Indeed, our previous finding highlighted the role of FAT10 
overexpression in causing chromosomal instability (CIN) through reduced 
localization of Mad2 at the kinetochore during mitosis, which then caused the 
abbreviation of mitosis duration, chromosome missseggregation and aneuploidy 
(Ren et al 2006). Further, inhibition of FAT10 expression caused normal Mad2 
localization at the kinetochore during pro-metaphase with significantly reduced 
aneuploid cells (Ren et al 2011b). Hence, based on these findings found so far, a 
more comprehensive understanding about the role of FAT10 in tumorigenesis as 
well as targeting its specific cellular function that contributes to tumorigenesis was 
necessary to be further investigated. 
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To study the role of FAT10 in tumorigenesis as well as finding the underlying 
mechanism, which contributes to tumorigensis, we chose to investigate the 
oncogenic properties of FAT10 in driving tumorigenesis through its effects in the 
important cellular functions such as in cell proliferation, migration, adhesion and 
invasion. Additionally, we also further examined, whether disruption of FAT10 
and Mad2 interaction alleviated the tumorigenic role of FAT10. So far, FAT10 has 
only been reported to cause aneuploidy and upregulated in tumors from cancer 
patients, however solid evidence about FAT10’s pro-malignancy properties in 
driving tumor growth and progression has never been elucidated. In order to give a 
comprehensive and direct evidence about the pro-malignancy role of FAT10 in 
tumorigenesis, in vitro assays such as wound healing assay, cell transformation 
assay, apoptosis assay, cell proliferation assay, invasion assay and adhesion assay 
were employed. In vivo approach using xenograft mice model was also used to 
further strengthen the in vitro assays.  
Since FAT10 crystal structure yet to be elucidated and FAT10 is a small 
protein molecule, in collaboration with A/P Song Jianxing, NMR study, which can 
be utilized to unveil the specific binding sites between FAT10 and Mad2 were 
employed in this thesis. Disruption of these binding sites by fusion-PCR-
mutagenesis study helped us to dissect the specific role of FAT10 in tumorigensis 
and specifically target the tumorigenic role of FAT10 without disrupting its 
physiological function. Furthermore, reduced Mad2 protein expression level or 
FAT10 protein overexpression allowed us to unravel, whether FAT10 exerted its 
oncogenic role through aberrant regulation and function of mitotic spindle 
checkpoint Mad2.  
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4.2 The significance of FAT10 overexpression in supporting cell proliferation, 
transformation and survival  
Current literature provides contradictory results on the role of FAT10 in cell 
survival role. FAT10’s pro-survival role has been supported by the following 
observations from various studies. Firstly, FAT10 was overexpressed in several 
types of cancers (Lee et al 2003, Lim et al 2006), Secondly, absence of FAT10 in 
knockout mice led to spontaneous apoptosis of lymphocytes (Canaan et al 2006), 
Thirdly, its high level of expression was correlated with colon cancer progression 
and recurrence (Yan et al 2010), and finally, FAT10 has also been proposed as  an 
epigenetic marker for liver neoplasia (Oliva et al 2008). All these studies only infer 
the pro-survival role of FAT10. However, concrete evidence on the role of FAT10 
in driving tumorigenesis has not yet been fully elucidated and shown. In contrast, a 
study from Raasi et al. reported a role for FAT10 in inducing apoptosis (Raasi et al 
2001).  A possible reason for this contradictory observationis that Raasi et al. used 
HeLa cells (cervical cancer cell line) and murine fibroblast cells in their studies, 
and there are no reports of FAT10 upregulation in these cells. In contrast, FAT10 
overexpression was reported in colon and liver cancer cells (Lee et al 2003, 
Lukasiak et al 2008a). Therefore, it is possible that the pro-survival role of FAT10 
maybe cell- or tissue-specific. Another possibility is that electroporation was used 
to introduce the ectopic expression of FAT10 in this study may have also 
contributed to the observed cell death. In our hands, the introduction of FAT10-
overexpressing plasmid by Lipofectamine in colorectal cancer cell lines (HCT116, 
SW620), liver cancer cell lines (HepG2, Hep3B), as well as infection of 
“immortalized” normal hepatocytes (NeHepLxHT, THLE) with adenovirus vector 
carrying FAT10 did not increase cell death or apoptosis.  
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Consistent with the possible pro-survival role of FAT10 reported by several 
studies mentioned earlier, we also found that FAT10 overexpression increased the 
proliferation of HCT116 cells and supported its malignant cell transformation in 
soft agar, where we observed more colonies in FAT10 overexpressing cells than in 
WT HCT116 cells. In contrast, reduction of FAT10 expression in FATi stable cells 
abated cell proliferation and also greatly impaired the malignant transformation of 
these cells, as evidenced by its ability to form colonies in soft agar. Two different 
methods (trypan blue exclusion cell counting and WST-1 assay) to measure the 
cell proliferation rate of FAT10 stable overexpressing cells, WT, and FAT10 
knockdown cells (FATi) were used in order to draw more conclusive results. The 
increase in cell proliferation rate as well as augmented self-anchorage independent 
growth were observed, when FAT10 was overexpressed, strongly supporting the 
role of FAT10 in driving cell malignancy. 
The characteristics of malignant cells are not only based on the ability of the 
cells to proliferate faster with enhanced malignant transformation ability alone, but 
it also depends on its ability to evade apoptosis. Thus, investigating the ability of 
FAT10 overexpressing cells to evade apoptosis is also as important as its 
proliferation and transformation ability. Importantly, we found that upon cytotoxic 
challenge, cells that overexpressed FAT10 were more resistant towards this 
cytotoxic induced cell death compared to its parental cells (WT HCT116). Taken 
together, these results have demonstrated that FAT10 upregulation increases cell 
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4.3 Importance of FAT10 as a determinant in enhancing cell migration, 
adhesion and invasion of cells  
Other than cell proliferation, cell survival and malignant transformation of 
cells, other important cellular features such as acquisition of adhesive, invasive and 
migratory capabilities are also important in tumor development and progression. 
Therefore we investigated, whether FAT10 also contributes to cell migration, 
adhesion and invasion? The first clues came from earlier studies, where high level 
of FAT10 expression was observed in stage II-III of colon cancer (Yan et al 2010) 
and a strong correlation was found between high FAT10 expression and cancer 
invasion, lymph node metastasis, distant metastasis, as well as the overall survival 
rate of colon and gastric cancer patients (Ji et al 2009, Qing et al 2011, Yan et al 
2010). Although, these correlative studies demonstrated a link between FAT10 
overexpression and the above-mentioned malignant features in tumors, a definitive 
study that demonstrate the role of FAT10 in increasing the cell invasion, adhesion, 
and migration remains to be investigated. 
To address this question, we performed cell invasion assay using transwell 
cell culture plate coated with matrigel to assess the capability of FAT10 cells to 
invade the matrigel and to migrate to the other side of the well. Remarkably, our 
data showed that FAT10 enhanced the cell invasiveness of HCT116 cells. Further, 
we also demonstrated that FAT10 supported the adhesion of cells to the 
extracellular matrix as well as significantly increased the cells migratory 
capabilities. Additionally, we found that stable cells overexpressing FAT10 
secreted a higher level of matrix metalloproteinase 9 (MMP-9) compared to WT 
and FAT10 knockdown cells using an ELISA assay. MMP-9 is widely known for 
its contribution in invasion and metastasis of tumor cells by degrading the 
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surrounding basement membrane and extracellular matrix barriers, which enables 
cells to migrate and spread to a distant site (Choi et al 2011, Egeblad and Werb 
2002, Wagenaar-Miller et al 2004). Taken together, these characteristics of 
malignant cells observed in FAT10 overexpressing cells supports the notion that 
FAT10 is an important determinant in malignancy rather than just a ”bystander”. 
As a whole, based on our in vitro observations, FAT10 protein likely plays an 
important role as a pro-malignant and pro-survival factor in tumorigenesis. 
 
4.4 Significance of FAT10 overexpression in vivo  
To reaffirm the oncogenic role of FAT10 observed in our in vitro study, we 
utilized a xenograft mouse model to evaluate the effect of FAT10 in vivo. In 
agreement with previous findings from FAT10 knockout mice that the 
lymphocytes of these knockout mice were more susceptible to spontaneous 
apoptosis (Canaan et al 2006), we also found that FAT10 overexpression greatly 
enhanced tumor growth. Bigger and heavier tumors were observed in mice injected 
with FAT10-overexpressing cells. In summary, based on our in vitro and in vivo 
findings, this thesis provides strong evidence that FAT10 functions as a novel pro-
survival and pro-malignant factor in tumorigenesis. Further in depth research on 
the mechanism of FAT10 that contributes to cell malignancy will provide new 
insights in cancer progression as well as present opportunities to target FAT10 in 
cancer. Therefore, based on our previous findings where FAT10 interaction with 
Mad2 as spindle mitotic checkpoint caused reduced localization of Mad2 at the 
kinetochore and subsequent aneuploidy, suggested FAT10 contribution in 
tumorigenesis was potentially through its interaction with Mad2, which then 
caused its aberrant function. To gain a better understanding whether this 
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mechanism was truly the fundamental mechanism that contributed to 
tumorigenesis, we further analyzed the potential role of FAT10 and Mad2 
interaction.  
 
4.5 Identification of specific Mad2 binding sites on FAT10 
As mentioned earlier that FAT10 and Mad2 interaction played an important 
role in FAT10’s pro-malignancy role and aneuploidy, we further extensively 
examined the importance of this protein-protein interaction. In order to find the 
specific site where MAD2 protein binds to FAT10 protein, we need to elucidate 
the FAT10 protein structure. Since the FAT10 crystal structure has not been 
resolved to date. Hence, in collaboration with A/P Song Jianxing from National 
University of Singapore (NUS), nuclear magnetic resonance (NMR) was employed 
to identify the specific amino acid residues that may be important for its interaction 
with Mad2. Since FAT10 and Mad2 are small protein molecules, which consist of 
17-kilo Dalton (kDa) and 24-kilo Dalton (kDa) respectively, they will form a 
complex that is less than 100 kDa, which is amenable to NMR elucidation of its 
protein-protein interaction. This is because small proteins allows detection of a 





HSQC spectrums, unlike large proteins, which has thousands of one dimensional 
spectrums and has a higher possibility of signal overlaps (Marintchev et al 2007, 




N HSQC spectrums were used to 
analyze the protein structure of an isotope-labeled protein (Liu et al 2005, 
Wuthrich 1990). Analysis of HSQC spectrum of 
15
N-labeled-FAT10 proteins 
obtained from the NMR study facilitated the “fingerprint” of each FAT10 amino 
acid residues. A subsequent addition of unlabelled-Mad2 protein into FAT10 
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protein solution allowed Mad2 to interact with FAT10 and caused the changes in 
FAT10’s amino acid equilibrium, which resulted in “shifting” in 1H-15N-HSQC 




N-HSQC spectrums from FAT10 protein 




N-HSQC spectrums from FAT10 and Mad2 complex, one 
can identify the specific amino acid residues in FAT10 that were responsible for its 





upon the addition of Mad2 protein. The NMR study unraveled two interaction 
regions within FAT10 that are important for binding with Mad2.  
To validate the results obtained from NMR study, fusion-PCR mutagenesis 
approach was employed to generate the mutant constructs and subsequently 
obtaining the various FAT10 stable mutants. After the successful generation of 
FAT10 overexpressing stable cells and its various mutant FAT10 stable cells, we 
used two different methods to examine, whether the NMR-predicted regions were 
specific for FAT10 and Mad2 binding and did not interfere with other FAT10’s 
interaction partners. We used co-Immunoprecipitation and in-situ proximity 
ligation assay (PLA) (Clausson et al 2011, Leuchowius et al 2011) to ascertain the 
protein-protein interaction between FAT10 and Mad2.  As shown, in Figure 3.10 
and 3.11, only mutations at both predicted Mad2 interaction regions in FAT10 
protein abolished its interaction with Mad2. Notably, mutation at these regions did 
not affect the interaction of FAT10 with the other proteins, which has been 
previously reported to interact with FAT10 either covalently such as with p62 and 
UBA6 proteins or non-covalently with HDAC6, and NUB1L proteins (Table1.3). 
In conclusion, the specific interaction sites between FAT10 and Mad2 protein that 
were important for their binding to each other was identified. The identification of 
specific regions in FAT10 that affect its binding with Mad2 but not other proteins 
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suggest that its other functions of FAT10 such as its function in immune response 
(Canaan et al 2006, Liu et al 1999b) (Ren et al 2011b) and protein degradation 
(Schmidtke et al 2006) may not be affected. Further investigation to reveal the 
effect of disruption of FAT10 and Mad2binding in tumorigenesis was also 
performed in this thesis and will be described in the next section. 
 
4.6 The implications of the abolishment of FAT10 and Mad2 binding in 
tumorigenesis 
Having identified the specific FAT10 amino acid residues that are important for its 
binding to Mad2 protein, we then further investigated the effect of disruption from 
FAT10 and Mad2 binding in influencing cellular functions and tumorigenesis 
(transformation, invasion, and migration abilities). In vitro assays such as cell 
proliferation assay, apoptosis assay, soft agar cell transformation assay, adhesion 
assay, wound-healing assay, F-actin staining and invasion assay were employed to 
check the importance of FAT10 and Mad2 binding in FAT10’s oncogenic role 
using the wild type FAT10 and mutant FAT10 that we generated.  
Several key observations were made: firstly, disruption of FAT10 and Mad2 
binding at both sites decreased the cell proliferation rate and cell malignant 
transformation ability. Secondly, this disruption also enabled the cells to be more 
prone to cytotoxic-induced cell death. Thirdly, adhesive properties of FAT10 
mutant stable cells were also significantly reduced compared to wild type FAT10 
stable overexpressing cells. Finally, the migratory and invasive capabilities of 
these mutant cells where FAT10 interaction with Mad2, is disrupted were also 
greatly abated. Taken together, all these in vitro experiments show that the 
abolishment of FAT10 and Mad2 binding can reverse the cell malignant features 
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of cancer cells. Hence, suggesting a novel mechanism of FAT10 that important in 
tumorigenesis. Our findings strongly suggest that its interaction with Mad2 
mediates FAT10 role in tumorigenesis. Targeting this mechanism through the 
disruption of FAT10 interaction with Mad2 reduced the pro-survival and pro-
malignant roles of FAT10 significantly. 
In corroboration with our in vitro findings mentioned earlier, we also observed 
a negative effect of the disruption FAT10 and Mad2 binding on tumor growth in 
xenograft mice model. Significantly, smaller tumors were observed in mice 
injected with FAT10 stable mutants, where its interaction with Mad2 is disrupted. 
However, mutations at only a single region of Mad2 interaction regions within 
FAT10 did not significantly reduce the size of tumors isolated from the nude mice 
3 weeks after subcutaneous injection of these FAT10 stable mutants into the 
flanking region of these nude mice. Thus, these in vivo observations have further 
strengthened our observation that the oncogenic role of FAT10 is largely 
attributable to its interaction with Mad2, and disruption of this interaction 
significantly reduced the malignancy of cancer cells. Having confirmed the 
significance of FAT10 and Mad2 interaction, we then asked, if the disruption of 
FAT10 and Mad2 binding site will also affects the rate of aneuploidy of the cells, 
since FAT10 overexpression has been previously reported to cause reduced 
localization of Mad2 at kinetochore during mitosis, which then led to aneuploidy. 
Interestingly, we discovered that the abolishment of FAT10 and Mad2 binding 
reduced cell aneuploidy based on our karyotyping profile of FAT10 mutant cells 
carrying mutations at both interaction sites. Moreover, we also demonstrated that 
these FAT10 mutants were unable to escape the mitotic arrest unlike their wild 
type FAT10 stable cells counterparts, which were able to induce a greater escape 
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from mitotic arrest. In concordance with our previous findings, we also found that 
mutations only at one region of FAT10 and Mad2 interaction regions did not 
increase the level of aneuploidy nor did it help the cells to escape from mitotic 
arrest. Hence, not only have we shown that complete disruption of FAT10 and 
Mad2 binding at both sites reduced the malignant attributes of the cells but we 
have also successfully demontrated its role in the reduction of aneuploidy, which is 
widely recognized to play a major role in oncogenesis (Hede 2005). In summary, 
through in vitro as well as in vivo studies we have clearly revealed the important 
mechanism of FAT10 that contributes to tumorigenesis. 
 
4.7 Aberrant Mad2 function is the mechanism for FAT10 to cause aneuploidy 
 Having shown that FAT10 overexpression induces aneuploidy in cells and 
disruption of FAT10 and Mad2 interaction reduces aneuploidy. Going forward, we 
examined whether FAT10 promoted aneuploidy through Mad2 or if there were any 
other mechanisms involved in this process? Through this investigation we then 
were able to dissect the specific mechanism of FAT10 that contributed in 
tumorigenesis. 
A reduction of Mad2 levels by siRNA or FAT10 overexpression was used to 
examine if FAT10-overexpressing cells phenocopied the effect of Mad2 knock 
down on aneuploidy. Remarkably, we found that FAT10 overexpression 
phenocopies Mad2 knockdown. Therefore, the results strongly suggest that 
FAT10’s role in aneuploidy is linked with aberrant Mad2 function. On the other 
hand, if aneuploidy observed in FAT10 overexpressing cells were not linked with 
dysregulation of Mad2 function than similar phenotypes from FAT10-
overexpressing cells and Mad2 knock down cells would not have been observed. 
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However, since FAT10 overexpression or Mad2 knockdown were able to reduce 
Mad2 level or caused an aberrant Mad2 function, a similar proportion of 
chromosome number were observed either when FAT10 was overexpressed, or 
when Mad2 was knocked down.  
Next, we further investigated, whether FAT10 overexpression or Mad2 
knockdown had also a similar effect on its ability to help cells escape mitotic 
arrest. Similar to our previous findings, we found that either FAT10 
overexpression or Mad2 knockdown were also equally efficient in enhancing the 
ability of the cells to escape from mitotic arrest. In summary, all the data presented 
in this thesis have highlighted the importance of FAT10 overexpression in driving 
tumorigenesis, as well as the fundamental mechanism in which FAT10 contributed 
to tumorigenesis, through its interaction with Mad2, which then aberrantly altered 
Mad2 function during cell cycle progression. 
 
4.8 The impact of our work on the field of cancer research 
Elucidating the role of FAT10 in tumorigenesis not only provided new 
insights on the ability of FAT10 to drive tumorigenesis and the role of FAT10 in 
promoting cell malignancy, but it also highlighted the important mechanism by 
which FAT10 initiates tumorigenesis, which is via Mad2-binding. We have shown 
that abrogation of the Mad2-binding function in FAT10 did not affect FAT10 
binding to its other interaction partners, therefore making the targeting residues 
within FAT10 that binds to Mad2 an attractive therapeutic option.  
FAT10 has been previously reported to be associated with inflammation as its 
expression was inducible by pro-inflammatory cytokines such as TNF-α and IFN-γ 
in immune cells and cancer cells (Liu et al 1999a, Lukasiak et al 2008b, Ren et al 
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2011a). Likewise, FAT10 was also highly expressed in organs of the immune 
system and inflammation-associated cancers (Bates et al 1997, Lee et al 2003). 
Interestingly, in the colorectal cancer cell line HCT116 induction of FAT10 
through TNF-α required NF-B activation (Ren et al 2011b). Anti-TNF- drugs 
such as adalimumab (humira), infliximab (remicade), and etanercept (enbrel) have 
been marketed and used to treat cancers. However, since TNF-α is part of immune 
system and it protects the body from infection, long-term treatment of TNF-α-
antagonist has been reported to increase a patient’s susceptibility to fatal infections 
(Frank et al 2009). Moreover, TNF-α inhibitors have been reported to have great 
adverse drug reactions (Fiorino et al 2011, Wolfe and Michaud 2004). Likewise, 
for NFkB inhibitors many other important cellular functions will be affected, since 
NFkB is a major transcription factor of many important genes. Therefore, targeting 
FAT10 directly may be a more favorable approach. 
Thus far the associations of FAT10 in tumorigenesis have been mostly 
inferential, based on correlative expression study of FAT10 in tumor samples. The 
direct evidence of FAT10’s ability as a driving force to initiate or drive the tumor 
growth and cell malignancy has not been examined. Although FAT10 has been 
previously reported to induce aneuploidy by binding to mitotic spindle checkpoint 
Mad2 and causing the reduction of its localization at the kinetochores during pro-
metaphase, it remains unclear whether FAT10 and Mad2 interaction is the key 
mechanism that can potentially drive cells from aneuploidy state to become 
cancerous. Our study has paved the way for the use of FAT10 as a potential 
therapeutic target in cancer. 
For the first time, the work in this thesis provided strong evidence to show that 
indeed FAT10 enhanced cancer cells malignancy by inducing cell growth, cell 
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survival, cell invasion, cell migration and cell aneuploidy. Additionally, FAT10 
overexpression initiated cell malignant transformation in non-tumorigenic cells. 
Abolishment of FAT10 and Mad2 interaction led to tumor regression and 
weakened cell malignancy. Thus our data gave us a more comprehensive 
understanding on FAT10’s mechanism in driving tumorigenesis. Characterization 
of FAT10 overexpression in the in vivo environment was also for the first time 
demonstrated in this thesis. Our findings on FAT10’s pro-malignancy role and its 
mechanism provided us with a new potential cancer therapeutic target. 
4.9 Conclusion and future perspectives 
Taken together, we have characterized the pro-malignancy function of FAT10. 
We have demonstrated that FAT10 hijacks the spindle checkpoint role of Mad2 
during mitosis through its interaction with Mad2, resulting in the delocalization of 
Mad2 from the kinetochores and leading to abnormal chromosomes segregation, 
aneuploidy, and finally cancer development.  
Importantly, we have successfully identified the specific Mad2 interaction 
sites on FAT10. This is a significant step in enabling the mechanisms by which 
FAT10 exerts its pro-malignancy effects. The use of FAT10 mutants with 
abrogated Mad2 binding in various cellular functional assays and xenograft mice 
model provided strong evidence that FAT10 induces tumorigenesis by binding to 
Mad2. 
We have found that mutating the Mad2-binding sites on FAT10 does not 
affect the interaction of FAT10 with its other interaction partners. This marks 
FAT10 as a potential therapeutic target for cancer. For future work, we propose the 
synthesis of a small-molecule FAT10 inhibitor which binds to the Mad2-binding 
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sites on FAT10 to create a steric hindrance effect, and thus, preventing Mad2 from 
binding to these sites. 
This would be useful in our effort to translate our findings from bench to bedside. 
Given that FAT10 is an ubiquitin-like protein which has been activated through a 
cascade of enzymes through its double glycine residues, a more in depth study 
about the role of these glysine residues in FAT10 pro-malignancy will also be 
important and interesting for future explorations. In addition, we propose that these 
studies on the pro-malignancy role of FAT10 be extended to non-tumorigenic cells 
in addition to using cancer cells. This will give us an insight on the role of FAT10 
on cancer initiation. 
In summary, in this thesis we have demonstrated FAT10’s ability in 
increasing the malignancy including tumor growth of colorectal cancer HCT116 
cells. In addition, using non-tumorigenic immortalized human neo-natal 
hepatocytes cells (NeHepLxHT), we were able to initiate the malignant cell 
transformation of these normal hepatocytes in soft agar, showing the capability of 
FAT10 in driving and initiating tumorigenesis. Based on our findings on the 
significance of disruption of Mad2 binding site on FAT10 in reducing tumor 
growth in vivo, our results have paved the way for the development of a potential 
drug that can specifically bind to these sites and prevent Mad2 binding to these 
sites without affecting FAT10’s interaction with its other interaction partners. 
Thus, our results demonstrated the translational potential of our study. 
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